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ABSTRACT 
BACKGROUND 
 Chronic kidney disease is the growing epidemic of the 21st century. With 
the rising burden of diabetes and hypertension, chronic kidney disease is 
becoming rampant in our country. About 40 – 50% of the death in chronic 
kidney disease patients is attributed to cardiovascular causes. Individuals with 
the most severe form of chronic kidney disease have a risk for cardiac death 15 
times higher than patients with preserved glomerular filtration rate. The two 
classical features of cardiac disease in end stage renal disease (ESRD) are 
atherosclerotic vascular disease and left ventricular hypertrophy. The prevalence 
of left ventricular hypertrophy is around 80% in a dialysis population. Multiple 
afterload and preload related factors act in the pathogenesis of this uremic 
cardiomyopathy, which once initiated, lead on to myocyte ischemia and 
myocardial fibrosis and eventually death. Hence if the risk factors which 
contributed to left ventricular hypertrophy in chronic kidney disease patients 
could be lined out, it would be possible to prevent and regress the left 
ventricular wall thickness. In our study, two variables glomerular filtration rate 
and the amount of proteinuria are used to predict the left ventricular mass index 
in chronic kidney disease. 
 
 
AIMS AND OBJECTIVES: 
1. To calculate the left ventricular mass index in CKD patients who are 
maintained on conservative medical management 
2.  To calculate the glomerular filtration rate of CKD patients using 24 hour 
creatinine clearance and Cockcroft Gault formula and the amount of 
proteinuria using urine spot PCR and 24 hour quantification. 
3.  To study whether there is a significant correlation between the amount of 
proteinuria and glomerular filtration rate to the left ventricular mass 
index. 
4. To also correlate the association between other variables in chronic 
kidney disease and left ventricular mass index. 
 
MATERIALS AND METHODS: 
 A total of 75 patients attending the Nephrology OP and admitted in the 
Nephrology ward satisfying the inclusion and exclusion criteria were included 
in the study over a period of 6 months. Blood samples and urine samples were 
drawn at the time of admission and in the Outpatient department for urine spot 
protein creatinine ratio calculation and renal function test.  24 hour urine 
collection was scrutinized and analysed for proteinuria quantification and 
creatinine clearance. Left ventricular mass was measured using 2D 
Echocardiography. Devereux formula was used for the calculation of left 
ventricular mass index. 
OBSERVATION AND RESULTS: 
 Among the variables studied age and sex of the patient, prevalence of 
diabetes and hypertension in the study population, systolic blood pressure, 
diastolic blood pressure, serum albumin and hemoglobin, serum alkaline 
phosphatase, total cholesterol and serum triglycerides, blood urea of the 
patients in the study group did not have a significant p value, suggesting that 
all these variables did not influence or predict the development of left 
ventricular hypertrophy in chronic kidney disease patients in our study. 
 The variables duration of chronic kidney disease, serum creatinine, 
creatinine clearance (24 hour urine estimation, Cockcroft Gault equation, 
and MDRD equation), and urine spot PCR and 24 hour proteinuria all had 
a significant p value demonstrating their predictive potential for left ventricular 
hypertrophy in chronic kidney disease. 
 Among the significant parameters, a statistically highly significant 
negative correlation was observed between declining GFR (Stage 4/5) and 
increased left ventricular mass index (p value < 0.001). Highly significant 
positive correlation was also observed with serum creatinine values and 
increased left ventricular mass (p value < 0.001). Regarding proteinuria, a 
highly significant positive correlation was obtained between urine spot protein 
creatinine ratio, 24 hour urine protein and the left ventricular wall thickness (p 
value < 0.001). These parameters were found to be significant in both univariate 
and multivariate regression analysis. 
CONCLUSION: 
1. Glomerular filtration rate and the amount of proteinuria significantly 
influence the left ventricular wall thickness in chronic kidney disease 
patients.  
2. Declining GFR had a strong negative correlation with left ventricular 
mass, where the amount of protein excreted positively predicted the 
significant risk of left ventricular hypertrophy in these patients.  
3. These predictors of LV mass could be easily measured and are highly 
sensitive and specific for the same.  
4. Hence routine measurement of these variables, and its correlation to left 
ventricular thickness could be easily ascertained compared to the costly 
investigations like cardiac MRI and Echocardiography.  
5. On arriving at a suspicion of possible LV hypertrophy, rigorous measures 
to reduce protein excretion and frequent hemodialysis session could 
improve patients survival from the deadly cardiovascular diseases. 
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   INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Chronic Kidney Disease is the burgeoning epidemic of the 21
st
 century. 
This disease is a potential threat to our country, both economy wise and as 
well as proportion wise. More than 50 million people in the world are 
afflicted by kidney disease. There are more than 2 million people all over the 
world who needs either dialysis or renal transplant for sustaining their life. 
But this fraction represents a meagre 10% of the deserving
 [1]
. The percentage 
of people in the early stages of disease, when the patient is a potential 
candidate for conservative management is around 11% of the adult 
population
 [2]
. The population that meets the spiteful end of untreated renal 
failure because of unaffordability is around 1 million per year
 [1]
. 
Looking into the risk factors, diabetes and hypertension top the rank 
list worldwide. With the rising burden of diabetes and hypertension, no 
wonder chronic kidney disease is becoming rampant in our country. The 
recent update of World Health Statistics in 2013 has proclaimed that one in 
three adults has hypertension and one in ten adults have diabetes worldwide
 
[3]
. Apart from the major risk factors mentioned, poverty and social 
deprivation are also of additional risk for developing chronic kidney disease 
in both developed and developing countries. 
 
 
 
Talking about costs, the global economic impact of chronic Kidney 
Disease is tremendous. At one end, the Government spends in billions for 
improving the survival rate and at the other end; there is loss of productivity 
because of the life consuming disease. The Medicare expenditure of the CKD 
population has doubled over the past 10 years. In the developed countries, 
3% of the health care budget every year is allocated for the management of 
chronic kidney disease and its complications
 [1]
. Where as in the developing 
and the underdeveloped countries, it is a dream yet to come true, not afforded 
by the dying population.  
The adverse outcome of chronic kidney disease includes kidney 
failure, complications due to decreased kidney function and cardiovascular 
diseases. About 40 – 50% of the death of CKD patients is attributed to 
cardiovascular causes
 [4]
. In particular, increased left ventricular wall 
thickness is found to underlie this predisposition for cardio-renal syndrome.  
Individuals with the most severe form of chronic kidney disease have a risk 
for cardiac death 15 times higher than patients with preserved glomerular 
filtration rate
 [4][5]
. 
Various studies done in kidney diseases suggest that early detection 
and treatment of CKD patients could prevent or at least delay these adverse 
outcomes
 [6]
.But the gruesome fact is CKD is often underdiagnosed and 
 
 
undertreated, because of the lack of clear definitions and classification, 
unpredictable course of the disease progression. 
But the increasing rate of morbidity and mortality of coronary artery 
disease in kidney disease make it necessary to develop further research in 
these populations. If the risk factors which contributed to left ventricular 
hypertrophy  in chronic kidney disease patients could be lined out, it would 
be a lot easier to treat them
[7][8]
.  
Therefore it’s high time now to check for the risk factors of left 
ventricular hypertrophy in end stage renal disease
 [9]
. This study is designed 
using the variables, proteinuria and glomerular filtration rate to predict the 
left ventricular hypertrophy in chronic kidney disease patients. So that, the 
early prevention of massive proteinuria and progressive deterioration in 
glomerular filtration rate with drugs and dialysis could improve the 
cardiovascular health of chronic kidney disease patients and sustain their 
struggle to live
 [10]
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
1. To calculate the left ventricular wall thickness in CKD patients who 
are maintained on conservative medical management. 
2. To calculate the glomerular filtration rate of CKD patients using 24 
hour creatinine clearance and Cockcroft Gault formula. 
3. To calculate the left ventricular wall thickness in CKD patients who 
are maintained on conservative medical management. 
4. To study whether there is a significant correlation between the amount 
of proteinuria and glomerular filtration rate to the left ventricular wall 
thickness in chronic kidney disease 
5. And also to correlate the association between other variables and left 
ventricular hypertrophy in chronic kidney disease patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   REVIEW OF    
   LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
HISTORICAL PERSPECTIVE 
                The concept of chronic kidney disease and its treatment began in 
the history as early as the 100 AD. The Romans were the first nephrologists 
who made dialysis machines from their bath tub. The idea was to “sweat out” 
the building up urea and creatinine by soaking in the bath tubs
 
[11]
.  Dr. Willem Kolff known today as “The Father of Dialysis” who created 
the first crude kidney machine in 1943 would have surely laughed at it
 [11]
.  
From the first living-related kidney transplant done by Dr. Joseph E. Murray 
in 1954 to the world’s first “triple swap” kidney transplantation done by 
surgeons at The Johns Hopkins Comprehensive Transplant Centre in 
February 2004, the field of nephrology has been ever growing
 [12]
. 
 
INCIDENCE AND SIGNIFICANCE OF CKD 
 The incidence of chronic kidney disease and its most adverse outcome, 
end-stage renal disease (ESRD) are increasing now in multiples. This is due 
to the fact that the most common causes of CKD, hypertension and diabetes 
are also increasing by the minute
 [12]
. So, the early identification and 
reduction of CKD population has become a matter of utmost importance.  
 
  
 
 
THE RISE OF DIABETICS WORLDWIDE 
The population plagued by diabetes exceeds 240 million all over the 
world.  This fraction is expected to shoot up to 380 million largely by 
2025
[13]
. The predisposing culprits include our unhealthy food practises and 
obesity, sedentary life and comforts of urbanization, growing and aging 
population. India followed by China, the United States, and Russia and Japan 
top the rank in diabetes worldwide. The bitter fact about this sweet disease is 
that more than half of the diseased people is unaware of their diagnosis and 
hence not treated. No wonder, around 40% of people with diabetes are 
assumed to develop CKD in the near future with the increased risk of 
cardiovascular diseases and other deadly complications of diabetes
 [13]
.  
 
THE GROWING HYPERTENSIVE POPULATION 
 A major cause of CKD, a global health worry which is supposed to 
worsen all the more in the immediate future is hypertension. As the people in 
the world are getting older, so is the prevalence of hypertension and kidney 
disease. One million population all over the world suffer from high blood 
pressure and are projected to increase to 1.56 million by year 2025
[13]
. In 
developing regions like India, the prevalence of hypertension is 80% which is 
a threefold rise from that of the developed countries (24%)
[13]
. 
 
 
 
 
THE MAGNITUDE OF CHRONIC KIDNEY DISEASE PROBLEM 
  The CKD prevalence in India has been reported between 0.16% and 
0.79%
 [14]
. The studies were designed to detect stage 3 – 5 CKD and thus the 
real prevalence of CKD is higher than this. The ESRD incidence has been 
reported to be 160–232 per million populations (pmp) and the projected 
ESRD prevalence was 785–870 per million populations [14]. “Screening and 
Early Evaluation of Kidney Disease” (SEEK), a community-based voluntary 
health screening program was started in India in 2006 and tests serum 
creatinine and urine analysis. SEEK reported a17.4% of CKD in Indian 
population (using an abbreviated modified diet in renal disease (MDRD) 
formula, a glomerular filtration (GFR) estimation formula
 [14]
. 
 The chronic kidney diseases accounts for 60% of all deaths worldwide. 
Eighty percentages of these deaths worldwide occur in low- and middle-
income countries. Globally, CKD is the 12th cause of death and the 17th 
cause of disability, respectively.  In India, the projected number of deaths due 
to chronic disease was around 5.21 million in 2008. This death toll is 
presumed to increase by 2020 to 7.63 million which accounts for 66.7% of all 
deaths
 [14]
. 
 
 
 
 
 
DEFINITION OF CHRONIC KIDNEY DISEASE 
Chronic kidney disease is defined as either kidney damage or 
decreased kidney function (decreased GFR) for 3 or more months. According 
to KDOQI guidelines, definition of chronic kidney disease includes 
1. “Kidney damage for ≥ 3 months, as defined by structural or functional 
abnormalities of the kidney, with or without decreased GFR, manifest by 
either pathological abnormalities; or markers of kidney damage, including 
abnormalities in the composition of the blood or urine, or abnormalities in 
imaging tests 
2. GFR < 60 mL/min/1.73 m2 for ≥ 3 months, with or without kidney 
damage”. 
TABLE 1: CLASSIFICATION OF CKD BASED ON K/DOQI 
GUIDELINES: 
 
Table 1 shows the classification of chronic kidney disease into 5 stages based 
on glomerular filtration rate (K/DOQI Guidelines) 
  
STAGE DESCRIPTION GFR (mL/min/1.73 m
2
) 
1 Kidney damage with normal or ↑ GFR ≥ 90 
2 Kidney damage with mild ↓ GFR 60 - 89 
3 Moderate ↓ GFR 30 - 59 
4 Severe ↓ GFR 15 - 29 
5 Kidney failure < 15 (or dialysis) 
 
 
POTENTIAL RISK FACTORS IN THE PATHOGENESIS OF CKD 
[18]
 
These factors can be further classified based on their role in pathogenesis 
FIGURE 1 
 
 
 
 
 
Figure 1 shows the three potential risk factors for developing chronic kidney 
disease. These factors play an important role in the pathogenic mechanism of 
chronic kidney damage. 
SUSCEPTIBILITY FACTORS 
These factors increase the susceptibility to kidney damage 
1. Older age 
2. Family history 
 
INITIATION FACTORS 
   
TABLE 2 
 
Diabetes 
Hypertension 
Systemic infections 
Urinary tract infections 
 
 
Urinary stones 
Recovery from acute renal injury 
Reduction in renal mass 
Autoimmune diseases 
Neoplasia 
Family history of chronic kidney disease 
Exposure to certain drugs 
Low birth weight 
 
Table 2 lists the initiation factors which play a vital role in initiating kidney 
damage in chronic kidney disease. 
Any of the above factors can initiate an injury/ damage to the kidney 
which acts as “the first hit” to the kidney. 
 
PROGRESSION FACTORS 
These factors cause worsening kidney damage and faster decline in kidney 
function after initiation of kidney damage 
 
 Higher level of proteinuria 
 Higher blood pressure level 
 Poor glycaemic control in diabetes 
 Smoking 
 
 
 
 
PATHOPHYSIOLOGY 
In chronic kidney disease, the pathologic process includes a double hit/ insult 
to the kidney: 
(1) INITIATING MECHANISMS[15] 
The aetiology of the initiating mechanism of injury to the kidney can 
be 
 A genetically determined abnormality in kidney structure, 
development or function 
 Inflammatory processes and deposition of immune complexes 
 Exposure to toxins 
 Diseases of the renal interstitium and tubules 
  
(2) PROGRESSIVE MECHANISMS[15] 
The common consequences that follow an insult/ injury to the kidney are as 
follows: 
 Hyper filtration  of  remaining nephrons 
 Hypertrophy of the viable nephrons 
Increased activity of the renin-angiotensin axis in the kidney, due to the 
stimulation of transforming growth factor (TGF) causes the initial short term 
adaptations. The other factors responsible for this effect are vasoactive 
hormones, growth factors and cytokines. 
 
 
FIGURE 2 
 
 
 
 
 
 
 
 
 
 
Figure 2 shows the secondary glomerular changes that occur following 
an insult to the kidney and reduction in nephron number. Focal adhesions and 
enlargement of capillary lumens are consequent to the hyper filtration and 
hypertrophy of the viable nephrons. 
However, these short-term adaptations become ineffective as the 
increased pressure and flow causes destruction of glomerular architecture. 
There is sclerosis of the glomerular membrane and the remaining nephrons 
dropout
 [15]
. This process explains the progressive decline in renal function 
following an isolated injury to the kidney. 
 
 
 
CARDIOVASCULAR MORBIDITY IN CHRONIC KIDNEY 
DISEASE: 
 Cardiovascular disease is an important cause of morbidity and 
mortality in patients at every stage of CKD. The incremental risk of 
cardiovascular disease in those with CKD ranges from 10- to 200-fold based 
on the stage of CKD. As a result, most patients with CKD succumb to 
cardiovascular disease before ever reaching stage 5 CKD
 [16]
. Thus, the focus 
of patient care in earlier CKD stages should be directed to prevention of 
cardiovascular complications 
FIGURE 3 
 
 
 
 
 
 
 
 
Figure 3 shows the increasing mortality rate as the stage of chronic 
kidney disease progresses. The patient has increased likelihood of dying 
rather than starting dialysis or reaching stage 5 chronic kidney disease. 
 
 
 
RISK FACTORS OF CARDIOVASCULAR DISEASES IN CKD
 [4] [17] 
 
 The risk factors for cardiovascular disease in chronic kidney disease 
has been divided as clinical and socio demographic factors. 
 TABLE3 
 
 
 
Table 3 lists the clinical and socio demographic risk factors for 
cardiovascular disease in chronic kidney disease. 
These above factors act in concert, predispose and progress to early 
atherosclerosis and vascular damage thereby causing cardiovascular disease 
in the chronic kidney disease population as depicted in the chart below. 
 
 
 
CLINICAL FACTORS 
Diabetes 
Hypertension 
Autoimmune diseases 
Neoplasia 
Systemic infections 
Reduction in renal mass 
SOCIODEMOGRAPHIC 
FACTORS 
Older age 
Ethnicity 
Exposure to chemical and 
environmental conditions 
Low income and education 
 
 
 
FIGURE 4 
 
 
 
 
 
 
 
Figure 4 shows the predisposing and progression factors which leads to 
vascular calcification and hence cardiovascular disease in chronic kidney 
disease. 
 
TRADITIONAL AND NON-TRADITIONAL RISK FACTORS: 
The risk factors for coronary vascular disease in chronic kidney disease 
can be classified as traditional cardiovascular risk factors and non-traditional 
risk factors which are specific for the underlying predisposition
 [19]
. 
 
The following table lists the traditional Vs. Chronic Kidney Disease-related 
factors potentially related to increased risk for Cardiovascular Disease 
 
 
 
TABLE 4:            TABLE 5: 
 
 
 
Table 4 lists the traditional risk factors for cardiovascular disease 
 
Table 5 lists the non-traditional (CKD related) risk factors for the 
development of cardiovascular disease in chronic kidney disease 
 
 
Traditional CVD Risk Factors 
Older age 
 Male gender 
White race 
Hypertension 
Elevated LDL cholesterol 
Decreased HDL cholesterol 
Diabetes mellitus 
Tobacco use 
Physical inactivity 
Menopause 
Psychosocial stress 
Family history of CVD 
CKD-Related (Non-traditional) CVD Risk 
Factors 
Type (diagnosis) of CKD 
Decreased GFR 
Proteinuria 
Renin-angiotensin system activity 
Extra-cellular fluid volume overload 
Abnormal calcium and phosphorus metabolism 
Dyslipidaemia 
Anaemia 
Malnutrition 
Inflammation 
Infection 
Thrombogenic factors 
Oxidative stress 
Elevated homocysteine 
Uremic toxins 
 
 
MECHANISM OF CARDIOVASCULAR DISEASE IN CKD 
Cardiac disease in CKD patients is a growing pandemic of the century
 
[20]
. Many individuals with chronic kidney disease die early of cardiovascular 
morbidity even before they realise the impact of the disease
 [21] [22]
. Coronary 
disease is diagnosed in 75% of adults who are started on dialysis
 [23]
. 
FIGURE 5 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 lists the causes of death in chronic kidney disease and the various 
cardiovascular mechanisms that culminate in the death of CKD patients. 
 
 
 
 
The above chart shows the proportion of mortality due to cardiovascular 
causes in chronic kidney disease. Various abnormalities like left ventricular 
hypertrophy, systolic dysfunction, dilated ventricles are common
 [24]
. But, the 
two classical features of cardiac disease in ESRD are atherosclerotic vascular 
disease and left ventricular hypertrophy
 [25]
. 
Accelerated atherosclerosis in CKD patients progressed as GFR kept 
decreasing. The major increase for cardiac disease and death occurred when 
the GFR dropped below 60ml/min
 [26]
. 
A second presentation of cardiac problem in CKD population is LVH 
(left ventricular hypertrophy)
 [27]
. The prevalence of increased left ventricular 
thickness is approximately 80% in a dialysis population
 [28]
. There is myocyte 
to arteriolar capillary mismatch in patients having left ventricular 
hypertrophy
 [29]
.  
There are two types of left ventricular hypertrophy
 
 Eccentric 
 Concentric  
Volume overloading of the ventricles causes dropout of cardiac 
myocytes which causes eccentric hypertrophy. Hypertension and other causes 
of increased systemic vascular resistance cause concentric hypertrophy of the 
ventricles
 [30]
. 
Diastolic dysfunction is the dominant LV physiology accompanying 
LVH
 [31]
. This results in a sharp increase in LV diastolic pressure with modest 
 
 
increments in LV volume. This physiology explains the lower threshold for 
pulmonary edema under these circumstances. Patients with LVH also often 
have a reduction in systolic function and this exposes the patient to the risk of 
sudden cardiovascular death
 [32]
. 
At the extreme edge of the cardiac diseases, cardiac arrthymias and 
sudden cardiac death
 [33]
 are more common in the elderly people. 
TABLE 6 
MECHANSIMS OF SUDDEN CARDIAC DEATH IN CHRONIC 
KIDNEY DISEASE 
Changes in the coronary microcirculation 
Impaired coronary reserve 
Reduced cardiac compliance 
Increased activity of sympathetic nervous system 
Increased concentration of Angiotensin II 
Dense myocardial fibrosis 
Changes in the concentration of electrolytes during dialysis 
 
Table 6 mentions the various mechanisms responsible for sudden  
cardiac death in chronic kidney disease. 
 
 
 
 
LEFT VENTRICULAR HYPERTROPHY
 [34]
 
Increased LV wall thickness known as LVH is a significant cause of 
heart disease in ESRD populations. LVH alters the mechanics of the 
myocardium, thereby altering the contractile mechanism and resulting in 
hypoxia of the heart itself, at the end predisposing to cardiac arrhythmia, 
diastolic dysfunction and progressing to overt heart failure. 
 
UREMIC CARDIOMYOPATHY
 [34]
 
The influence of impaired renal failure on cardiac function is better 
known by the term Uremic cardiomyopathy. Cardiac hypertrophy is the 
signature manifestation of this uremic cardiomyopathy. Although this may be 
due to excess serum levels of urea, impaired GFR levels of even as little as 
50% increased the cardiovascular mortality to 5 fold
 [25]
. The exact 
pathogenesis of increased ventricular wall thickness remains uncertain. 
 
PATHOPHYSIOLOGY OF LVH
 [35]
: 
The pathogenesis and causes of LVH/ CAD in ESRD is complicated 
due to the fact that there are independent risk factors complicating both 
cardiac disease and chronic kidney disease like diabetes, hypertension and 
high oxidant stress
 [36]
. 
 
 
 
 
The pathophysiology of LVH in CKD is dealt under three headings  
1. Afterload related[37] [38] 
 Systemic arterial resistance[39] 
 Increased systolic blood pressure[40] 
 Increased diastolic blood pressure[40] 
 Large vessel compliance (aortic calcification)[41] [42] 
2. Preload related[43] 
 Expansion of LV volume (salt/ fluid loading)[44] 
 Anaemia  [45] 
 Large flow arteriovenous fistula[46]  
3. Neither afterload nor preload related 
 
AFTERLOAD RELATED FACTORS 
One hypothesis suggested pressure overload as a cause of cardiac 
hypertrophy due to the prevalence of increased blood pressure in patients 
with chronic kidney disease 
[47]
. However experimental correction of high 
blood pressure in lab rats with renal injury did not stop the progression of left 
ventricular hypertrophy. In human studies, cardiac hypertrophy occurred in 
kidney disease patients even after the control of blood pressure 
[48] [49]
. The 
following are the proposed hypothesis: 
 
 
1. High calcium phosphorus product present in CKD reduces the aortic 
compliance. This increases the stress on the left ventricle causing 
increased afterload
 [51] [52]
. 
2. Vasoactive peptides (Endothelin/ Angiotensin II) are elevated in the serum 
acting as potent vasoconstrictors. These peptides also exacerbate coronary 
vessels vasoconstriction. 
3. Fetuin A is the recently proposed factor to play a major role in the 
calcification scheme. It is supposed to increase the mineralization of 
vascular smooth muscle
 [53]
. 
4. In diabetic nephropathy, a blood pressure-independent increase in LV 
mass index occurs. In those receiving conventional dialysis, both 
medication and dialytic therapy successfully reduce ventricular mass and 
these treatments are effective even in normotensive patients
 [54] [55]
.                
5. The important signal transduction molecules responsible for left 
ventricular hypertrophy are 
a. endothelin 1 (ET 1) 
b. parathormone (PTH)[56]     
c. tumour necrosis factor-alpha (TNF α) 
d.  leptin  
e. interleukin 1 alpha (IL 1α) 
f.  interleukin 6 ( IL 6)[57] 
 
 
The above said conditions basically cause activation of intracardiac 
renin-angiotensinogen system which causes myocardial cell thickening and 
concentric left ventricular remodelling. There is also increased oxidative 
stress and xanthine oxidase activation predisposing to LVH
 [58] [59]
. 
 
PRELOAD RELATED FACTORS
:
 
Another potential cause of uremic cardiomyopathy is volume overload 
which triggers LVH by increasing its left ventricular end diastolic pressure
 
[60]
.These conditions predispose to lengthening of the myocardial cell and 
eccentric hypertrophy. Thus, both the above factors act synergistically to 
produce cardiovascular morbidity in ESRD
 [61]
. 
FIGURE 6 
 
 
 
 
 
 
 
Figure 6 shows the preload and afterload factors which contribute to the 
process of cardiac hypertrophy. 
 
 
 
OTHER MISCELLANEOUS FACTORS 
1. Hyperhomocystinaemia [62] 
Increased serum homocyteine levels are associated with left ventricular 
thickness in chronic kidney disease. 
2. Vitamin D deficiency 
Due to the lack of active Vitamin D in chronic kidney disease, renin 
angiotensin system is activated which causes secondary hyperparathyroidism. 
This further leads to the development of hypertrophy of the ventricles and 
accelerated systemic hypertension.Studies done in the past show significant 
regression of left ventricular mass following treatment with active vitamin D 
supplements in end stage renal disease patients.  
3. Activation of mTOR[23] 
This is described in detail in the molecular mechanism of left ventricular 
hypertrophy. 
4. Renin Angiotensinogen system[63] 
Increased levels of angiotensin II causes hypertrophy of the cardiac 
myocytes probably through myocardial stretch irrespective of the blood 
pressure level. 
5. Phosphate levels 
Higher phosphate loads are associated with vascular calcification and 
increased aortic impedance which contribute to the left ventricular 
hypertrophy in chronic kidney disease. 
 
 
6. Markedly elevated Parathormone levels[64] 
Left ventricular hypertrophy occurs in both primary and secondary 
hyperparathyroidism and is directly proportional to its levels in CKD. 
7. Carnitine deficiency. 
8. Sympathetic Nervous System Activation 
9. Cytokine/Hormone/Catechol production- (aldosterone, endothelin-1, 
TNFα, Leptin. Il-1α, Il-6, TGFβ, nor-epinephrine) 
10. Gender 
 
Regardless of the underlying cause, be it afterload or preload or 
miscellaneous, the following steps are the dictum in ESRD. 
 
FLOWCHART 1 
 
 
 
 
 
 
 
 
 
MYOCARDIAL HYPERTROPHY AND MYOCYTE ISCHEMIA 
 
ACTIVATION OF CELLULAR APOPTOTIC AND 
AUTOPHAGIC SIGNALS [66] 
 
INCREASED PRODUCTION OF EXTRACELLULAR MATRIX  
 
PATHOLOGY OF LEFT VENTRICULAR 
HYPERTROPHY [65] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flowchart 1 shows the various end stage processes that occur following left 
ventricular hypertrophy that results in cardiovascular mortality. 
 
 
 
 
 
INTERMYOCARIDAL CELL FIBROSIS 
 
PIMPAIRMENT IN CONTRACTILITY AND STIFFENING OF 
MYOCARDIAL WALL 
 
DIASTOLIC DYSFUNCTION 
 
DILACARDIOMYOPATHY/ SYSTOLIC/ DIASTOLIC 
CONGESTIVE HEART FAILURE [67] 
 
DISTURBANCES IN THE ELECTRICAL CIRCUITRY OF HEART 
 
VENTRICULAR ARRHYTHMOGENESIS [67] 
 
 
 
 
MOLECULAR MECHANISMS
 [23]
 
Cardio tonic steroids (CTS) are the recently studied molecules. They are of 
low molecular weight of 500 daltons, which can be filtered by a 
semipermeable membrane. These cardio tonic steroid particles are dialyzable 
which explain how hemodialytic process alone reversed cardiac hypertrophy 
without altering intravascular volume or reducing blood pressure. 
Ouabain and marinobufagenin are such endogenous CTS which interact with 
the alpha subunit of Na+ K+ ATPase Trans membrane protein. These both 
compounds play a major role in the blood pressure regulation, cardiac 
contractility and cardiac hypertrophy. 
Intracellular signalling proteins and extracellular signal regulated kinases 
(ERK) are activated in response to increased concentrations of 
marinobufagenin which causes the development of uremic cardiomyopathy. 
Experimental evidence suggested that the mTOR (mammalian target of 
Rapamycin) was involved in the development of pressure overload- 
stimulated cardiac hypertrophy
 [23]
. Rapamycin, a direct inhibitor of mTOR 
blocked the development of left ventricular hypertrophy in patients with 
increased afterload. 
 
 
 
 
LV MASS MEASUREMENT 
1. Physical examination may reveal the shift of the point of maximum 
impulse. Postero-anterior view of chest radiograph may reveal increased 
cardiothoracic index. This is a simple, easy, inexpensive and insensitive 
form of evaluating left ventricular mass. 
2. The first non-invasive test was the electrocardiogram. This method was 
insensitive but specific method 
3. Serum Troponin-T levels correlate to the left ventricular mass in any 
patient.
[68]
. 
4. Serum Atrial and Brain Natriuretic Peptides are significant markers of 
hypertrophy as the serum levels of these peptides are augmented 
following a stretch response of the myocytes
 [68]
. 
5. Echocardiography 2D echo/ M mode are used for left ventricular mass 
calculation. 2D echo is more accurate than M mode. M mode 
overestimates the presence of increased LV Mass (due to volume changes 
and geometry in ESRD)
]69] [70]
 
6. 3D echo gives precise measurement of left ventricular wall thickness, left 
ventricular volume and ejection fraction
 [71] [72]
. 
7. Cine computed CT measures LV mass accurately. The disadvantage is 
radiation exposure and limited availability. 
 
 
8. The gold standard for assessment of LV dimension is cardiac magnetic 
resonance imaging (CMRI). Left ventricular mass, volume and pattern of 
LVH independent of geometric assumption and myocardial fibrosis can be 
found out
 [69]
. 
COMPARISON OF ECHOCARDIOGRAPHY VS CARDIAC MRI IN 
THE STUDY OF LEFT VENTRICULAR HYPERTROPHY 
M-Mode (1 D), 2 D and 3 D Echocardiography is the commonly used 
methods of quantifying left ventricular mass in patients. But in patients who 
are on dialysis, calculation of LVmass by these methods can be erroneous 
due to influence of volume changes associated with hemodialysis. On the 
contrary, 3DEchocardiograms tend to overestimate the left ventricular mass 
due to asymmetric remodeling of ventricles in some patients
 [73][74]
.  
FIGURE 7 
 
 
 
 
 
The above picture shows a normal ventricle on Echocardiography 
 
 
 
 
 
 
 
 
Increased left ventricular mass is seen in the above echocardiography 
FIGURE 8 
 
 
 
 
 
   Normal Ventricles   Hypertrophied ventricles 
Figure 7 & 8 show pictures comparing a normal ventricle with a thickened 
and hypertrophied ventricle measured using echocardiography. 
 
 
Cardiac MRI with contrast is the gold standard investigation in the evaluation 
of left ventricular hypertrophy. But the disadvantage of this investigation is 
that, it cannot be performed with contrast (gadolinium) in patients in end 
stage renal disease. 
FIGURE 9 
 
      MRI image showing thickened & 
      hypertrophied ventricular wall 
 
 
 
 
      MRI image of a normal ventricle 
 
 
Figure 9 shows a MRI image of a hypertrophied ventricle with increased 
ventricular wall thickness and a normal ventricle. 
 
 
 
PREVENTION AND TREATMENT 
The basic goals in the treatment of chronic kidney disease are: 
1. To reduce the progress of the kidney disease itself 
2. To prevent the extra renal complications such as cardiovascular disease 
and stroke 
MANAGEMENT OF CHRONIC KIDNEY DISEASE 
Since diabetes mellitus and hypertension are the two most frequent causes of 
advanced CKD, no wonder cardiovascular disease predominate in chronic 
kidney disease. There are various measures suggested to treat both the 
traditional and non-traditional cardiovascular risk factors in CKD patients
 [4]
. 
These include hypertension, elevated serum level of homocysteine, which 
promote dyslipidaemia. The role of "inflammation" causing endothelial 
damage and accelerated atherosclerosis is more important in patients with 
kidney disease. However, effective control of the risk factors is the only 
weapon possible in the treatment for these patients until the nature of disease 
progression and mechanism of complications in CKD and its treatment are 
better understood. 
 
 
 
 
TREATMENT OF HYPERTENSION INDUCED RENAL DISEASE
 [15] 
Reducing intraglomerular hypertension and proteinuria
 
Following an initial insult to the kidney, short term adaptive responses like 
increased glomerular filtration and glomerular hypertrophy occurs. But since 
the underling inciting cause is not resolved, the responses become 
maladaptive progressing to chronic kidney damage
 [15]
. Therefore control of 
systemic and glomerular hypertension is an important milestone in the 
treatment of CKD. Persistent elevation of blood pressure causes proteinuria 
through increased excretion, thus worsening of kidney damage. Hence, 
antihypertensive therapy slows the progression of kidney damage by 
decreasing the intraglomerular blood pressure as well as through decrease of 
proteinuria excretion
 [75]
. In fact, the efficacy of the antihypertensive 
treatment is established by its ability to decrease protein excretion in the 
urine and subsequent progression of GFR decline. 
Blood pressure of 125/75 mmHg is the target in CKD patients with 
proteinuria. The preferred antihypertensives are the renin-angiotensin system 
inhibitors (ACE inhibitors/ ARBs)
 [76] [77]]
. These drugs reduce both the 
intraglomerular hypertension and as well as protein excretion
 [78]
. These drugs 
are effective in slowing the progression for both diabetic and non-diabetic 
CKD. The second groups of drugs preferred are the calcium channel blockers 
 
 
(Diltiazem Verapamil) when proteinuria is insignificant and the 
intraglomerular pressure is less prominent. 
DECREASING THE RACE OF DIABETIC RENAL DISEASE
 [15]
 
Control of Blood Glucose 
 Maintaining euglycemic status decreases the decline in renal function and 
the progression of the disease. The recommended value is a pre-prandial 
glucose of 90 – 130 mg/dl and HBA1C value of less than 7%. 
Control of Blood pressure and proteinuria 
Hypertension is an important risk factor in the progression of diabetic 
nephropathy. Micro albuminuria is an important predictor of cardiovascular 
mortality and kidney disease. Hence antihypertensive drugs are used to 
reduce albuminuria and diminish the progression of normotensive diabetic 
patients. In particular, use of renin angiotensin blockers has a superior rule in 
renoprotection in diabetes
 [79]
. These effects are mediated by reducing 
intraglomerular pressure and blockade of RAS pathways through inhibition 
of TGF-β mediated pathways. 
MANAGEMENT OF CARDIOVASCULAR DISEASE IN CKD 
The following measures are suggested in the control and treatment of 
cardiovascular risk factors
 [18]
: 
 
 
1. Regular daily physical activity and dietary modification including salt 
restriction, protein enriched diet are important measures in the early stage 
of the disease
 [80]
. 
2. Meticulous control of volume status is the measure of utmost importance. 
Control of the extracellular volume requires sodium restriction and 
diuretics. The preferred drugs are loop diuretics
 [81] [82]
. 
3. Another measure suggested for maintaining volume status is long duration 
of dialysis periods or extra sessions of dialysis should be planned 
[83]
. 
4. The preferred hemoglobin range is between 10 – 12 g/dl and that of the 
haematocrit should be of minimum 30
[84]
. The above parameters should be 
achieved using small and divided doses of erythropoietin and parenteral 
iron
 [85] [86] [87]]
. 
5. Maintaining euglycemic status is important in diabetic patients. High 
blood pressure and proteinuria complicating diabetes should be treated 
with a hypertensive inhibiting the renin angiotensin system, either an 
angiotensin converting enzyme inhibitor or an angiotensin receptor 
[88] [89]
. 
6. Angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers is the preferred antihypertensive due to their action on the both 
intraglomerular hypertension and reduction of proteinuria. The target 
systolic blood pressure is 130 – 140 mmHg [90]. 
 
 
7. The LDL cholesterol should be lowered to <100 mg/dl in dialysis patients 
and <70 mg/dl in patients with known coronary disease. For control of 
hyperlipidaemia, if dietary measures are not sufficient, lipid-lowering 
medications, such as statins, should be used.  
8. Maintaining the calcium phosphorus product is necessary to prevent 
vascular calcification and aortic impedance. This could be achieved 
through calcium supplementation and removal of the excess phosphate 
through phosphate binders
 [56]
. 
9. The desired serum phosphorus level to maintain the calcium phosphorus 
product is 4 – 6 mg/dl [56]. Serum levels of phosphorus can be reduced 
using phosphate binders, so as to maintain the calcium phosphorus 
product. 
10. Due to the falling calcium level and hyperphosphatemia, secondary 
hyperparathyroidism is a common manifestation causing renal 
osteodystrophy. The preferred serum PTH value is 500 pg/ml.  Severe 
hyperparathyroidism should be treated with intravenous calcitonin
 [64]
. 
11. Chronic kidney disease causes vitamin D deficiency due to the lack of the 
formation of active vitamin D there by causing bone resorption and 
osteomalacia. This could be avoided by active Vitamin D 
 
 
supplementation. (serum levels of 30 ng/ml of ergocalciferol is 
preferred)
[91]
. 
12. Patients suffering from both coronary disease and kidney disease should 
be treated with a combination of low-dose aspirin and β blockers. Other 
potential nephrotoxic NSAIDs should be avoided. 
13. In patients considered to be at high risk of developing adverse events like 
obstructive sleep apnoea, prolonged QT interval, and severe left 
ventricular hypertrophy, prophylactic use of cardio-selective blockers (e.g. 
Carvedilol) should be added. 
14. Patients at risk of sudden cardiac death due to ventricular fibrillation 
should have an implantable cardiac defibrillator (ICD). 
15. Frequent and longer dialysis period including nocturnal haemodialysis, 
daily in-centre haemodialysis is strongly encouraged
 [93]
. Studies have 
shown that regular hemodialysis could cause regression of left ventricular 
hypertrophy. 
16. The course of left ventricular hypertrophy in haemodialysis patients 
should be monitored every 12 -18 months, every 2 years in conservatively 
managed CKD patients 
[94]
. 
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MATERIALS AND METHODS 
SETTING    : Government Royapettah Hospital, Chennai 
COLLABORATIVE 
DEPARTMENT   : Department of Nephrology, GRH  
     Department of Cardiology, GRH 
STUDY DESIGN   : Observational Study 
PERIOD OF STUDY  :  April 2013 to October 2013 
SAMPLE SIZE   :  75 cases  
INCLUSION CRITERIA: 
All Chronic kidney disease irrespective of the aetiology 
EXCLUSION CRITERIA: 
1. Age less than 18 years 
2. History of cigarette smoking  
3. History of alcohol consumption 
4. Obesity 
5. Patients receiving maintenance hemodialysis treatment 
6. Patients with arterio-venous fistulae 
 
 
7. Post renal transplant status 
8. Aortic stenosis/ aortic insufficiency 
9. Hypertrophic obstructive cardiomyopathy 
10. Athletic training 
Cases and Controls were selected after considering the above inclusion and 
exclusion criteria 
ETHICAL CLEARANCE:  Obtained 
INFORMED CONSENT 
All the cases in the Study Groups were informed about the nature of the 
study. Members who were willing to participate in this study were included 
after getting their written informed consent. 
METHODOLOGY 
  Patients admitted in the Nephrology ward and those patients attending the 
Nephrology Outpatient department of Government Royapettah Hospital were 
chosen as cases. A total of 75 cases that satisfied the inclusion and exclusion 
criteria above were included in the study over a period of 6 months.  
 A Data collection form was prepared to note the Name, Age, Sex, 
Occupation, Address, Complaints, Past Medical History, Smoking, 
Alcoholism, Drug Intake and other relevant history. General Examination 
 
 
with examination of the Vital Signs, Cardiac, Respiratory, Abdomen and 
Central Nervous System were done. Each Patient’s clinical profile was noted.  
LABORATORY INVESTIGATIONS 
  Blood samples and urine samples were drawn at the time of admission and 
in the Outpatient department for urine spot protein creatinine ratio calculation 
and renal function test.  24 hour urine collection was scrutinized and analysed 
for proteinuria quantification and creatinine clearance.  
 Left ventricular mass was measured using 2D Echocardiography.  
Devereux formula was used for the calculation of left ventricular mass index. 
STATISTICAL ANALYSIS 
 Data was entered in Microsoft Excel Spreadsheet and analysed.  
Data analysis was done with the use of standard SPSS software. Descriptive  
Statistics were used to calculate the frequency, mean and standard deviation.  
Students’’ values was applied for significance. Significance was considered if 
the ‘p’ value was below 0.05. 
CONFLICT OF INTEREST 
     There was no conflict of interest 
FINANCIAL SUPPORT:  Nil 
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DEFINITIONS USED IN THE STUDY 
SERUM CREATININE VALUE: 
0.7 to 1.3 mg/dL for men  
 0.6 to 1.1 mg/dL for women 
URINE CREATININE VALUE: 
Urine creatinine (24-hour sample) values can range from 500 to 2000 
mg/day. Results depend greatly on age and amount of lean body mass 
CREATININE CLEARANCE FORMULA: 
[Urine creatinine (mg/dL)] × [24-Hour Urine Volume  
(mL/day)/1440 (min/day)] 
[Serum Creatinine (mg/dL)] 
COCKCROFT GAULT FORMULA: 
(140 – Age) × Mass (in kilograms) × [0.85 if female] 
72 × Serum Creatinine (in mg/dL) 
 
 
 
 
 
 
DEFINITION OF PROTEINURIA 
TABLE 7 
URINE COLLECTION METHOD NORMAL PROTEINURIA 
24-Hour Excretion <300 mg/day >300 mg/day 
Spot Urine Protein-to-Creatinine Ratio <200 mg/g >200 mg/g 
 
Table 7 shows the normal and pathologic range of proteinuria measured by 
24 hour protein excretion and urine spot protein creatinine ratio. 
MODIFIED DEVEREUX FORMULA 
Left ventricular mass was calculated using the American society of 
echocardiography formula modified by Devereux  
LVmass:  0.8 (1.04 ([LVIDD + PWTD + IVSTD]
3
- [LVIDD]
3
))+ 0.6 
 LVIDD = Left Ventricular Internal Diameter in Diastole 
 PWTD = Posterior Wall Thickness in Diastole 
 IVSTD = Interventricular Septum Thickness in Diastole 
 
 
 
BODY SURFACE AREA 
The DuBois and DuBois formula: 
BSA (m
2
) = 0.20247 × Height (m)
 0.725
 × Weight (kg)
 0.425 
LEFT VENTRICULAR MASS INDEX 
Left ventricular mass (g) 
Body surface area (m
2
) 
Left ventricular hypertrophy was defined in absolute terms as LVMI >134 
g/m2 in men and >110 g/m2 in women 
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OBSERVATION AND ANALYSIS 
STUDY POPULATION CHARACTERISTICS 
A total of 75 patients of chronic kidney disease were included in this study of 
which 35 were females and 40 were males. Both male and females between 
ages 18 to 60 years were included in the study. 
TABLE 8: NO.OF MALE AND FEMALE PATIENTS IN THE STUDY  
 
 
 
 
 
Table 8 shows the frequency and percentage distribution of male and female 
in the study population. 
This frequency table says that almost equal numbers of male and female 
patients participated in this study. The male population represented 53.33% 
of the study while the female population represented 46.67% of the study 
group. 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid       F 35 46.67 46.67 46.67 
M 40 53.33 53.33 100 
Total 75 100 100  
 
 
  FIGURE 10: SEX DISTRIBUTION IN 
THE STUDY POPULATION 
 
 
 
 
 
 
 
Figure 10 shows a pie chart demonstrating equal distribution of male and 
female in the study population. 
TABLE 9: AGE WISE DISTRIBUTION OF PATIENTS 
 
 
Table 9 shows the 
distribution of the patients in each age group beginning from 18 to 59.This 
frequency table shows that patient in all age group are evenly distributed in 
the study population.  14 patients are present in the age group 18-29. The 
number of patients in the age group 40 to 49 is 25. 18 people are there in both 
30-39 age groups and 50-59 age groups. 
AGEGROUP 18-29 30-39 40-49 50-59 
TOTAL 14 18 25 18 
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TABLE 10: SEX DISTRIBUTION IN VARIOUS AGE GROUPS 
 
 
 
 
 
 
Table 10 shows the frequency distribution of male and female in the different 
age group. Regarding the sex distribution in the divided age groups, both the 
male and female patients are equally distributed in all age groups in this study 
population. 
 AGEGROUP 18-29 30-39 40-49 50-59 
MALE  7 10 16 7 
FEMALE  7 8 9 11 
TOTAL  14 18 25 18 
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Figure 12 is a column chart showing the distribution of male and female in 
the different age group of the study population. 
DURATION OF CKD IN THE STUDY POPULATION 
A frequency table correlating the duration of chronic kidney disease and the 
number of patients in each group is formulated. 
TABLE 11: NO. OF PATIENTS Vs DURATION OF CKD 
Duration  of CKD(years) 1 2 3 4 5 6 7 8 
No. of Patients 5 14 17 17 16 5 1 1 
Table 11 shows the frequency distribution of patients based on the duration 
of chronic kidney disease. More number of patients is having chronic kidney 
FIGURE 12: SEX DISTRIBUTION IN THE DIFFERENT 
 AGE GROUP OF THE STUDY POPULATION 
 
 
disease of the duration 2 – 5 years. A chart showing this distribution is as 
follows: 
 
Figure 13: is a column chart showing the distribution of patients based on 
their duration of disease. 
TABLE 12:  PREVALENCE OF DIABETES AND HYPERTENSION  
IN THE STUDY POPULATION 
 
 
 
 
Table 12 shows the prevalence of diabetes and hypertension in the study 
population. The number of diabetics in the study population of 75 is 35. 
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DURATION OF CKD 
 
NO. OF PATIENTS
TOTAL STUDY POPULATION 75 
NO. DIABETICS 35 
NO. OF HYPERTENSIVES 40 
NO. OF BOTH DIABETIC     
AND HYPERTENSIVE 
21 
 
 
TOTAL STUDY POP
NO. DIABETICS
NO. OF
HYPERTENSIVES
Hypertensive comprises around 40 of the total study group. Patients with the 
both risk factors are evenly distributed in the group. Number of patients 
harbouring both the risk factors of diabetes and hypertension are 21. 
 
 
 
 
 
 Equal number of hypertensive and diabetics has participated in this study. 
There is no significant difference between these two risk factors in the study.      
 
TABLE 13: STAGE WISE DISTRIBUTION OF CKD PATIENTS  
IN THE STUDY GROUP 
 MALE FEMALE TOTAL 
STAGE OF CKD    
1 1 1 2 
2 6 8 14 
3 11 10 21 
4 9 10 19 
5 13 6 19 
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Table 13 shows the frequency distribution of male and female in the different 
stages of chronic kidney disease. 
 In the above frequency table, patients are classified into groups based on the 
stage of chronic kidney disease. The staging is based on the glomerular 
filtration rate obtained from the creatinine clearance formula. 
 
 
 
 
 
 
 
Figure 15 column chart shows the sex distribution of patients in each stage of 
the disease. 
The majority of the study group is distributed between the stage 2 and above 
up to the stage of end stage renal disease. 
 
FIGURE 15: SEX DISTRIBUTION IN THE VARIOUS 
 STAGES  
OF CHRONIC KIDNEY DISEASE 
 
 
TABLE 14: DESCRIPTIVE ANALYSIS 
 N Range Minimu
m 
Maximu
m 
Mean Std.deviation 
AGE 75 37 19 56 41 10 
DURATION OF CKD 75 7 1 8 4 1 
STAGE OF CKD 75 4 1 5 4 1 
SYSTOLIC BLOOD 
PRESSURE 
75 42 98 140 124 13 
DIASTOLIC BLOOD 
PRESSURE 
75 20 70 90 81 5.2 
SERUM ALBUMIN 75 1.4 2.1 3.5 2.84 0.36 
HEMOGLOBIN 75 4.3 5.7 10 8.4 1 
SERUM ALKALINE 
PHOSPHATASE 
75 240 180 420 289 69 
SERUM 
CHOLESTEROL 
75 280 98 378 201 64.9 
SERUM 
TRIGLYCERIDES 
75 217 80 297 167 53.3 
BLOOD UREA 75 182 28 210 87.2 41.7 
SERUM CREATININE 75 12.2 0.8 13 4.7 3.1 
24 HR CREATININE 
CLEARANCE 
75 95 3 98 36 27 
CREATININE 
CLEARANCE(CCG) 
75 89 4 93 34 24 
CREATININE 
CLEARANCE(MDRD) 
75 83 4 87 33 24 
URINE SPOT PCR 75 20.43 0.57 21 7.33 6.42 
 
 
24 HR PROTEINURIA 75 13249 571 14000 5992 4300 
BODY SURFACE 
AREA 
75 0.7339
6 
1.3225 2.05646 1.5982
9 
0.17693 
 
Table 14 lists the descriptive variables which are to be compared in the 
normal and abnormal ventricular mass group. 
Descriptive variables in the study were age, sex, duration of chronic kidney 
disease, prevalence of diabetes and hypertension, systolic blood pressure, 
diastolic blood pressure, serum albumin, hemoglobin, serum alkaline 
phosphatase, total cholesterol, serum triglycerides, blood urea, serum 
creatinine, 24 hour creatinine clearance, estimated creatinine clearance by 
Cockgraft-gault formula and MDRD equation, stage of CKD, urine spot 
creatinine ratio, 24 hour proteinuria quantification and waist circumference.  
Patients in this study were divided into two group based on their left 
ventricular mass index. Female with LV mass index more than 110 g/m
2 
 and 
male with LV mass index more than 134 g/m
2
  were categorized as abnormal/ 
increased left ventricular mass group and those patients with values below 
than this were categorized as the group with normal left ventricular mass. The 
above said descriptive variable of each patient is compared in either group 
and significance of “p” value of the descriptive variable is noted. 
 
 
 TABLE 15: PREVALENCE OF INCREASED LEFT VENTRICULAR 
MASS INDEX IN THE STUDY POPULATION 
 
 
 
 
 
Table 15 shows the distribution of patients with normal and increased 
ventricular mass based on the stage of chronic kidney disease. 
In the study population, 29 patients had normal ventricular mass and 46 
patients had increased left ventricular mass. The stage wise distribution of 
patients with normal and increased left ventricular mass is above. The 
prevalence of increased/ abnormal left ventricular mass is stage 1 and 2 
CKD is nil. In stage 3, the prevalence of increased left ventricular mass is 
17.4% among the study population. The prevalence of increased left 
ventricular mass in stage 4 of CKD is 41.3% and in stage 5 of CKD, 41.3% 
 
 
 
Stage of CKD Normal Abnormal 
1 2 0 
2 14 0 
3 13 8 
4 0 19 
5 0 19 
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Figure 16 shows the distribution of patients in each stage with normal and 
increased left ventricular mass. In this chart, the progressive increase in the 
prevalence of increased left ventricular mass is evident as the stage of chronic 
kidney disease progresses. 
TABLE 16: PREVALENCE OF INCREASED LVMI IN THE MALE 
AND FEMALE STUDY POPULATION 
Stage of CKD Increased LV mass 
 Male Female 
1 0 0 
2 0 0 
3 3 5 
FIGURE 16: PREVALENCE OF VENTRICULAR MASS  
Vs STAGES OF CHRONIC KIDNEY DISEASE 
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.In the above table, sex wise distribution in the left ventricular thickness is 
documented. The numbers of female patients with increased LV mass are 5 in 
stage 3, 10 in stage 4 and 6 patients in stage 5 of CKD. The numbers of male 
patients in the increased LVmass group are 3 in stage 3, 9 in stage 4 and 13 in 
stage 5 of CKD. 
 
 
 
 
 
 
 
 
The above chart displays the progressive in left ventricular mass as the stage 
of CKD increases, with equal incidence in both male and female patients. 
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FIGURE 17: PREVALENCE OF INCREASED LV MASS 
 IN THE MALE AND FEMALE STUDY POPULATION 
 
 
TABLE 17: SEX * LVMI               
  LVMI Total  
  Normal 
Abnorm
al  
p value 
Sex Male Count 15 25 40 0.824 
  % within 
Sex 
37.5% 62.5% 100.0% 
  % within 
LVMI 
51.7% 54.3% 53.3% 
 Female Count 14 21 35 
  % within 
Sex 
40.0% 60.0% 100.0% 
  % within 
LVMI 
48.3% 45.7% 46.7% 
Total Count 29 46 75 
 % within 
Sex 
38.7% 61.3% 100.0% 
 % within 
LVMI 
100.0% 100.0% 100.0% 
 
Table 17 shows the frequency distribution of male and female in the study 
group with regard to normal and abnormal ventricular mass. 
 
 
 
 
 
FIGURE 18: SEX Vs LVMI 
 
 
Figure 18 compares the sex distribution between the normal and increased 
left ventricular mass group. 
The “p” value between the two groups male and female with regard to the 
variable left ventricular mass index is 0.824. Hence the sex difference 
regarding the left ventricular wall thickness was not significant. 
 
TABLE 18: AGE * LVMI            
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Normal Abnormal
LVMI
Sex Male
Sex Female
 LVMI N Mean Std. deviation p value 
Age in years Normal 29 41.21 9.507 0.912 
 Abnormal 46 40.89 10.963 
 
 
 
Table 18 shows the frequency distribution of age in both the normal and 
increased left ventricular mass group.The difference in the age distribution 
between the two groups with normal and abnormal ventricular mass was not 
statistically significant. The p value for age in either of the study group is 
0.912 which is not at all significant value. 
TABLE 19: DURATION OF CHRONIC KIDNEY DISEASE * LVMI 
 LVMI N Mean Std. Deviation p value 
Duration of CKD Normal 29 3.52 1.184 0.028 
Abnormal 46 3.7 1.685 
 
Table 19 shows the frequency distribution of patients in the two groups based 
on the duration of chronic kidney disease and p value for the same. 
There was a significant correlation between the two groups in the duration of 
chronic kidney disease. This implies that the left ventricular mass increases 
progressively as the number of years of disease increases. The p value for 
duration of chronic kidney disease in either group is 0.28 which is 
statistically significant. 
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Figure 19 shows the increasing prevalence of left ventricular hypertrophy in 
the study population as the stage of the chronic kidney disease increases 
TABLE 20: DIABETES MELLITUS * LVMI           
  LVMI 
Tota
l 
 
  
Norma
l 
Abnorma
l  
p 
value 
DM Yes Count 15 20 35  
0.486   % 
within 
DM 
42.9% 57.1% 
100.
0% 
  % 
within 
LVMI 
51.7% 43.5% 
46.7
% 
 No Count 14 26 40 
  % 
within 
DM 
35.0% 65.0% 
100.
0% 
 
 
  % 
within 
LVMI 
48.3% 56.5% 
53.3
% 
Total Count 29 46 75 
 % 
within 
DM 
38.7% 61.3% 
100.
0% 
 % 
within 
LVMI 
100.0
% 
100.0% 
100.
0% 
 
Table 20 shows the distribution of diabetic population in the both the normal 
and increased left ventricular mass group and the p value for the same. 
FIGURE 20: DIABETES Vs LVMI 
 
Regarding the distribution of diabetes in both the normal and abnormal left 
ventricular mass group, there was no significant relation. The p value for the 
number of diabetes in either group is 0.486 which is not at all statistically 
significant. 
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TABLE 21: SYSTEMIC HYPERTENSION * LVMI 
  LVMI Total  
  
Norma
l 
Abnor
mal  
p value 
SHT Yes Count 15 25 40  
0.824   % 
within 
SHT 
37.5% 62.5% 100.0% 
  % 
within 
LVMI 
51.7% 54.3% 53.3% 
 No Count 14 21 35 
  % 
within 
SHT 
40.0% 60.0% 100.0% 
  % 
within 
LVMI 
48.3% 45.7% 46.7% 
Total Count 29 46 75 
 % 
within 
SHT 
38.7% 61.3% 100.0% 
 % 
within 
LVMI 
100.0% 100.0% 100.0% 
 
 
 
 
 
 
FIGURE 21: SYSTEMIC HYPERTENSION Vs LVMI 
 
Figure 21 compares the frequency distribution of hypertensive patients in the 
both groups of normal and increased left ventricular mass. 
Regarding the distribution of hypertension in both the normal and abnormal 
left ventricular mass group, there was no significant relation. The p value for 
the number of diabetes in either group is 0.824 which is not at all statistically 
significant. 
TABLE 22: SYSTOLIC BLOOD PRESSURE VS LVMI 
Systolic BP LVMI N Mean Std. 
deviation 
p value 
 Normal  29 124.55 12.07 0.65 
 Abnormal 46 122.87 13.055 
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Table 22 compares the variable systolic blood pressure in the normal and 
abnormal LV mass group and the p value for the same. 
The mean systolic blood pressure in the normal left ventricular mass group is 
124.55 and in the increased left ventricular mass group are 122.87.  There 
was no significant difference in systolic blood pressure in both group, and the 
p value is0.65 which is not statistically significant. 
TABLE 23: DIASTOLIC BLOOD PRESSURE VS LVMI 
Diastolic BP LVMI N Mean Std. 
deviation 
p value 
 Normal  29 81.93 5.669 0.131 
 Abnormal 46 79.87 4.87 
 
Table 23 compares the variable diastolic blood pressure in the normal and 
abnormal LV mass group and the p value for the same 
 The mean diastolic blood pressure in the normal left ventricular mass 
group is 81 and in the abnormal left ventricular mass group is 79. There was 
no statistically significant difference in either of the group when compared 
with the variable diastolic blood pressure. The p value is 0.131 
 
 
 
 
TABLE 24: SERUM ALBUMIN VS LVMI 
Serum Albumin LVMI N Mean Std. 
deviation 
p value 
 Normal  29 2.934 0.3866 0.12 
 Abnormal 46 2.781 0.3308 
 
Table 24 compares the variable serum albumin in the normal and abnormal 
Left Ventricular mass group and the p value for the same 
When compared to the variable serum albumin in either of the group of 
normal and increased left ventricular mass group, there was no significant 
difference in the groups. The mean serum albumin in the normal LVmass 
group is 2.934 and in the increased left ventricular mass group, the serum 
albumin is 2.781. The p value is 0.12 which is not statistically significant.\ 
TABLE 25: HEMOGLOBIN VS LVMI 
Hemoglobin LVMI N Mean Std. 
deviation 
p value 
 Normal  29 8.33 1.052 0.406 
 Abnormal 46 8.44 1.042 
Table 25 compares the distribution of the variable hemoglobin in both the 
normal and increased left ventricular thickness group. 
The variable, hemoglobin is generally reduced in chronic kidney disease 
group. The mean hemoglobin in the normal ventricular mass group is 8.33 
 
 
and in the increased ventricular mass group are 8.44. The p value for this 
variable in both the group is 0.406 which is not statistically significant. 
TABLE 26: SERUM ALKALINE PHOSPHATASE VS LVMI 
Serum Alkaline 
Phosphatase 
LVMI N Mean Std. 
deviation 
p 
value 
 Normal  29 285.86 77.969 0.451 
 Abnormal 46 290.65 64.339 
 
Table 26 compares the distribution of patients in the two groups of normal 
and increased left ventricular mass based on the variable, serum alkaline 
phosphatase. 
There was no statistically significant difference in either group when 
compared with serum alkaline phosphatase. The mean serum alkaline 
phosphatase is 285 in the normal LV mass group and in the abnormal group 
are 290. The p value is 0.451 which is not at all statistically significant. 
TABLE 27: SERUM CHOLESTEROL AND LVMI 
Serum 
Cholesterol 
LVMI N Mean Std. 
deviation 
p value 
 Normal  29 206.07 67.928 0.667 
 Abnormal 46 198.52 64.181  
 
 
 
Table 27 compares the serum cholesterol levels in both the group of normal 
and increased left ventricular mass and the p value for the same. 
The mean serum cholesterol in the normal ventricular mass group is 206 and 
in the increased ventricular mass group are 198. There was no significant 
difference in either group and the p value for this variable is 0.667 which is 
not statistically significant. 
TABLE 28: SERUM TRIGLYCERIDES VS LVMI 
Serum Triglycerides LVMI N Mean Std. 
deviation 
p value 
 Normal  29 166.24 51.465 0.895 
 Abnormal 46 167.07 55.569 
 
Table 28 compares the serum triglyceride levels in both the group of normal 
and increased left ventricular mass and the p value for the same. 
The mean serum triglyceride in the normal group is 166 and in the abnormal 
group are 167. There is no significant difference in either group and the p 
value is 0.895 
 
 
 
 
 
TABLE 29: BLOOD UREA VS LVMI 
Blood Urea LVMI N Mean Std. 
deviation 
p value 
 Normal  29 76.97 48.252 0.41 
 Abnormal 46 93.67 36.531 
 
Table 29 compares the serum urea levels in both the group of normal and 
increased left ventricular mass and the p value for the same. 
The serum urea in the normal ventricular mass group is 76 and in the 
abnormal group are 93. There is no statistically significant difference in 
either group when compared with blood urea concentration the p value is 
0.41. 
TABLE 30: SERUM CREATININE VS LVMI 
Serum Creatinine LVMI N Mean Std. 
deviation 
p value 
 Normal  29 1.872 0.7745 <0.001 
 Abnormal 46 6.515 2.6802 
  
Table 30 compares the serum creatinine levels in both the group of normal 
and increased left ventricular mass and the p value for the same. 
The mean serum creatinine in the normal ventricular mass group is 1.872 and 
in the increased left ventricular mass group is 6.515. The p value comparing 
 
 
0.00
50.00
100.00
150.00
200.00
250.00
0 5 10 15
SERUM CREATININE VS LVMI 
LVMI
serum creatinine in either of the group is less than 0.001 which is statistically 
highly significant 
 
 
 
 
 
 
 
Figure 22 shows a line diagram comparing the variables, left ventricular mass 
index and serum creatinine. 
In the above chart, the serum creatinine is compared with left ventricular 
mass index. There was a positive correlation between the two variables, as 
suggested by the progression of the line upwards and to the left. As the serum 
creatinine increased, the left ventricular mass increased. 
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TABLE 31: 24 HOUR CREATININE CLEARANCE VS LVMI 
24 hrcreatinine 
clearance 
LVMI N Mean Std. 
deviation 
p value 
 Normal  29 64.28 20.898 <0.001 
 Abnormal 46 17.96 9.328 
 
Table 31 compares the 24 hour creatinine clearance levels in both the group 
of normal and increased left ventricular mass and the p value for the 
same.The normal group has a mean 24 hour creatinine clearance of 64 and in 
the increased left ventricular mass group; the mean value of 24 hour 
creatinine clearance is 17 which has a statistically significant p value of less 
than 0.001. 
 
 
 
 
 
 
Figure 23 shows a line diagram comparing the variables, left ventricular mass 
index and 24 hour creatinine clearance. 
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The above chart confirms the hypothesis that a declining glomerular filtration 
rate has a significant correlation with the left ventricular mass index. The 
correlation is a negative correlation, showing the decrease in creatinine 
clearance, is associated with increasing ventricular mass. 
TABLE 32: CREATININE CLEARANCE BY CCG VS LVMI 
creatinine 
clearance (CCG) 
LVMI N Mean Std. 
deviation 
p value 
 Normal  29 61.17 15.531 <0.001 
 Abnormal 46 17.39 9.332 
 
Table 32 compares the creatinine clearance levels (by Cockcroft Gault 
formula) in both the group of normal and increased left ventricular mass and 
the p value for the same. The creatinine clearance measured by Cockcroft 
Gault formula also had a significant difference in either of the group with a p 
value of less than 0.001 which is statistically highly significant. The mean 
value in the normal group is 61 and in the abnormal group are 17. 
 
 
 
 
 
 
Figure 24 shows a line diagram comparing two variables, creatinine clearance 
and left ventricular mass index. 
The creatinine clearance has a negative correlation with left ventricular mass 
index group. As the creatinine clearance declined, the ventricular mass index 
progressed which is suggested by the above chart. 
TABLE 33: CREATININE CLEARANCE BY MDRD VS LVMI 
creatinine 
clearance (MDRD) 
LVMI N Mean Std. 
deviation 
p 
value 
 Normal  29 58.69 14.912 <0.001 
 Abnormal 46 17.09 9.904 
  
Table 33 compares the creatinine clearance levels (calculated by MDRD 
equation) in both the group of normal and increased left ventricular mass and 
the p value for the same. 
When the creatinine clearance measured by MDRD equation is compared in 
either of the group, the mean clearance value is 58 in the normal group and in 
the increased LV mass group, the mean clearance value is 17 which has a 
statistically highly significant p value of less than 0.001. 
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Figure 25 shows a line diagram comparing the variables, creatinine clearance 
and left ventricular mass index. 
In this chart, there is progressive increase in left ventricular mass index group 
as the creatinine clearance kept decreasing showing a significant negative 
correlation between the two groups. 
TABLE 34: URINE SPOT PCR VS LVMI 
Urine spot PCR LVMI N Mean Std. 
deviation 
p 
value 
 Normal  29 1.8224 0.96362 <0.001 
 Abnormal 46 10.8097 6.01479 
 
Table 34 compares the urine spot PCR ratio levels in both the group of 
normal and increased left ventricular mass and the p value for the same. 
 
 
0
50
100
150
200
250
1 4 7 10131619222528313437404346495255586164677073
Ur.PCR
LVMI
In the above table, a statistically significant p value of less than 0.001 was 
obtained between the two groups with regard to urine spot PCR. The mean 
value of spot PCR in the normal group was 1.8 and in the increased left 
ventricular mass group was, 10.8 thus identifying it as an independent 
predictor of increased left ventricular mass. 
 
 
 
 
 
 
 
Figure 26 shows a line diagram comparing the variable, urine spot PCR ratio 
and left ventricular mass index. 
The table shows the positive relation between the two variables, urine spot 
PCR and Left ventricular mass. As the amount of urine PCR increases, the 
left ventricular thickness increases. 
 
FIGURE 26: COMPARISON BETWEEN URINE SPOT PCR AND LVMI  
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TABLE 35: 24 HOUR PROTEINURIA VS LVMI 
24 hour proteinuria LVMI N Mean Std. 
deviation 
p 
value 
 Normal  29 1821.62 969.84 <0.001 
 Abnormal 46 8621.74 3457.595 
 
Table 35 compares the 24 hour proteinuria levels in both the group of normal 
and increased left ventricular mass and the p value for the same. 
In the above table, there was a statistically significant difference in the 
variable proteinuria, when compared in the two groups of normal and 
abnormal/ increased left ventricular mass. The mean proteinuria in the group 
with normal LV mass was 1821 and in the left ventricular hypertrophy group 
was 8621 giving a highly significant p value of less than 0.001. 
 
 
 
 
 
 
FIGURE 27: COMPARISON BETWEEN 24 HOUR  
PROTEINURIA AND LVMI 
 
 
 
Figure 27 shows a line diagram comparing the variables, 24 hour proteinuria 
and left ventricular mass index. 
The above chart shows the positive correlation between the amount of 
proteinuria and left ventricular mass, thus signifying its importance as an 
independent risk factor and predictor of left ventricular hypertrophy. 
TABLE 36: BODY SURFACE AREA VS LVMI 
Body surface area LVMI N Mean Std. 
deviation 
p 
value 
 Normal  29 1.5962 0.16146 0.713 
 Abnormal 46 1.5996 0.18959 
 
Table 36 compares the variable, body surface area in both the group of 
normal and increased left ventricular mass and the p value for the same. 
There was no significant difference between the two groups of normal and 
increased ventricular mass, when compared to the variable body surface area. 
The p value was not significant (0.713) indicating that the body surface area 
did not vary significantly between the two groups and it is not an predictor of 
left ventricular hypertrophy. 
 
 
 
 
TABLE 37: CORRELATION BETWEEN SERUM CREATININE AND 
CREATININE CLEARANCE  
  24 CrCl ECrCl MDRD CrCl 
Serum 
creatinine 
Sig. (2-tailed) <0.001 <0.001 <0.001 
 N 
75 75 75 
 
Table 37 shows the correlation between the variables, serum creatinine and 
creatinine clearance measured by various methods (24 hour creatinine 
clearance, Cockcroft Gault equation and MDRD equation) 
TABLE 38: COMPARISON OF THE CREATININE CLEARANCE 
OBTAINED BY VARIOUS METHODS 
  24 CrCl ECrCl MDRD CrCl 
24 CrCl Sig.(2 tailed) - <0.001 <0.001 
 N 75 75 75 
ECrCl Sig.(2 tailed) <0.001 - <0.001 
 N 75 75 75 
MDRD CrCl Sig.(2 tailed) <0.001 <0.001 - 
 N 75 75 75 
Table 38 shows the comparison between the creatinine clearance of the study 
population obtained by various methods (24 hour creatinine clearance, 
Cockcroft Gault equation and MDRD equation)  
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 The serum creatinine value showed a negative correlation with the 
creatinine clearance values measured by various methods. 24 hour creatinine 
clearance, Cockcroft Gault, MDRD equation clearance value decreased as 
serum creatinine values steered up. The correlation showed a highly 
significant p value less than 0.001. 
TABLE 39: CORRELATION BETWEEN URINE SPOT PCR AND 24 
HOUR URINE PROTEIN QUANTIFICATION 
  24 hour proteinuria 
Urine spot PCR Sig. (2-tailed) <0.001 
N 75 
  
Table 39 shows the comparison between the variables, urine spot PCR and 24 
hour proteinuria. 
 
 
 
 
 
 
 
 
Figure 28 is a scatter diagram showing the distribution of the variable 24 hour 
proteinuria based on the stages of chronic kidney disease. 
The correlation between the variables urine spot protein creatinine ratio and 
24 hour proteinuria shows a highly significant p value of less than 0.001. This 
proves the reliability of using urine spot PCR value as a surrogate marker of 
24 hours proteinuria. 
TABLE 40: CORRELATION BETWEEN SERUM CREATININE AND 
PROTEINURIA  
  Urine spot PCR 24 hour proteinuria 
Serum 
Creatinine 
Sig. (2-tailed) <0.001 <0.001 
N 75 75 
 
Table 40 shows the comparison of the variables urine spot PCR and 24 hour 
proteinuria with regard to serum creatinine. 
 In this table, serum creatinine values are compared with proteinuria 
(urine spot PCR and 24 hour proteinuria). There is a highly significant p 
value of less than 0.001 between the two variables, indicating the positive 
correlation that amount of proteinuria increases as serum creatinine increases. 
 
 
 
TABLE 41: CORRELATION BETWEEN CREATININE 
CLEARANCE AND PROTEINURIA  
  Urine spot PCR 24 hour proteinuria 
24 Creatinine 
Clearance 
Sig.(2 tailed) <0.001 <0.001 
 N 75 75 
Creatinine Clearance 
(CCG) 
Sig.(2 tailed) <0.001 <0.001 
 N 75 75 
Creatinine Clearance 
(MDRD) 
Sig.(2 tailed) <0.001 <0.001 
 N 75 75 
 
Table 41 shows the comparison between the variables, urine spot PCR, 24 
hour proteinuria and creatinine clearance obtained by various methods (24 
hour creatinine clearance, Cockcroft Gault equation and MDRD equation) 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
 
In the above table, correlation between creatinine clearances measured by 
various methods is compared with proteinuria. The proteinuria quantification 
includes both urine spot protein creatinine ratio and the 24 hours urine 
proteinuria. The methods used for calculating creatinine clearance are 24 
 
 
hour creatinine clearance, Cockcroft Gault equation and MDRD (Modified 
Diet in Renal Disease) equation. When the creatinine clearances measured 
are compared with the amount of protein excreted, there was a negative 
correlation. As the Glomerular filtration rate declined, the amount of 
proteinuria increased indicating end stage renal disease. The negative 
correlation was statistically significant with a p value of less than 0.001 
which is highly significant. 
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DISCUSSION 
 Cardiovascular disease is the killer under the hood in chronic kidney 
disease. The incidence of adverse events and mortality due to cardiovascular 
causes in chronic kidney disease is fifteen times higher when compared to the 
normal population. When the underlying cause to this increased 
predisposition is analysed, left ventricular hypertrophy ideally known as 
uremic cardiomyopathy plays the major role. Hence, if the risk factors which 
increased the ventricular mass in a CKD patient could be identified; it could 
pave a way for preventing and delaying left ventricular hypertrophy and 
thereby cardiovascular mortality in these patients. 
In our study, we included 75 cases of known chronic kidney disease on 
conservative management. The percentage of females in the study group was 
46% and males were 53%. Patients with uncontrolled hypertension, on 
maintenance hemodialysis, on arteriovenous fistula and other factors which 
influenced the left ventricular mass independently were excluded from the 
study.   
Investigation like serum albumin, alkaline phosphatase, total cholesterol and 
triglycerides, hemoglobin, serum urea and creatinine, creatinine clearance, 
urine spot PCR  and proteinuria were measured in the study population.  
 
 
 
  The patients in the study had proteinuria ranging from physiological 
limits to nephrotic range and massive protein excretion. The glomerular 
filtration rate in the study population ranged from near normal to end stage 
renal disease. These variables were used to predict the risk for left ventricular 
hypertrophy in chronic kidney disease patients, which predicts future 
cardiovascular events. 
Left ventricular hypertrophy was measured using 2D echocardiography by 
Devereux formula in the study population. Around 61% of the patients in this 
study had increased left ventricular mass on echocardiography.  
The limit for left ventricular hypertrophy for females was > 110 g/m2and 
60% of the female cases in the study had increased left ventricular mass. The 
mean GFR was 25 ml/min and mean proteinuria was > 3.5 g in females that 
was associated with left ventricular hypertrophy.  
 The cut-off for left ventricular hypertrophy in males was >134 g/m2 and 
62.5% of the male cases had increased left ventricular mass according to 
Devereux Formula. The mean GFR was 20 ml/min and the mean proteinuria 
was more than 7 g. 
 
 
 
 
AGE AND LVMI 
In our study, there was no significant association between different age 
groups and increased left ventricular mass. Chronic kidney disease had an 
equal distribution among all the age groups in our study population. 14 
patients are present in the age group 18-29. The number of patients in the age 
group 40-49 is 25. 18 people are there in both 30-39 age groups and 50-59 
age groups, the aetiology being inherited and congenital in the younger age 
group, with diabetes and hypertension dominating the picture in the older age 
groups. The p value between the groups for the variable age was not 
statistically significant (p = 0.912). 
But, in a study by John D. Hamett et al
 [95]
, the study showed that age was 
associated with the development of LVH after the initiation of dialysis. They 
found that cases that developed left ventricular hypertrophy were 
significantly older than controls at baseline; the reason cited was that the 
aging ventricle is more sensitive to the hypertrophic stimulus of an elevated 
systolic blood pressure. 
 In a similar study by Lawrence P. McMahon et al
 [99]
, age factor was 
found to contribute to the initial presence of LV hypertrophy. The effects of 
age contributed to disease progression through both an increase in large 
vessel stiffness and age relation reduction in glomerular filtration rate. 
 
 
SEX AND LVMI 
In our study, no gender variation was found between the two groups of 
normal and increased left ventricular mass. Almost equal number of male 
(53.33%) and female (46.67%) patients participated in the study. The left 
ventricular mass index calculated by Devereux formula, was based on body 
surface area which considerably reduced the gender bias due to body mass 
index. The mean left ventricular mass was taken as 110 g/m2 and above in 
females whereas in males, increased left ventricular mass was taken to be 
more than 138 g/m2 and above.Hence accounted for the gender bias, we did 
not find any significant association between the gender distributions of left 
ventricular hypertrophy in our patients. The p value was not statistically 
significant between the two groups (p = 0.824). 
In a study by Robert N. Foley et al
 [98]
, male gender was found to have 
increased left ventricular mass compared to the female study population. The 
possible explanation was that the higher body mass index led to increased left 
ventricular mass in the male gender. 
DURATIONOF THE DISEASE AND LVMI 
 In our study, left ventricular hypertrophy was found frequently in patients 
with longer duration of chronic kidney disease. The p value for the duration 
 
 
of CKD in the two groups of normal and increased left ventricular mass was 
statistically significant (p = 0.028). 
In a study by Yilmaz BA et al
 [102]
, left ventricular hypertrophy was found 
frequently among patients with longer duration of chronic kidney disease. 
The prevalence of left ventricular hypertrophy progressively increased as the 
duration of the disease increased 
STAGE OF THE DISEASE AND LVMI 
In our study, 61% of the study population had increased left ventricular mass 
in the predialysis period.In an article by Kimura et al, a Japanese journal, 
left ventricular hypertrophy which is a strong predictor of mortality in 
chronic kidney disease patients is present in over 70% of patients 
commencing dialysis.  
In our study, the prevalence of left ventricular hypertrophy was 17.4% in 
stage 3 CKD, 41.3% in stage 4 and 41.3% in stage 5 CKD.The prevalence  of  
LVH in the Kimura et al studywas 22.7% in stage 3,43.6% in stage 4, and 
48.3% in stage 5 (creatinine clearance > 10 mL/min) (p = 0.15)which tends to 
increase with progression of renal decline. Thus, from the above variables, a 
significant association was found between the stages of chronic kidney 
disease and left ventricular hypertrophy indicating a progressive decline in 
glomerular filtration rate as the disease progresses through the various stages. 
 
 
DIABETES AND LVMI 
In our study of 75 patients, 35 were diabetics. The number of diabetics with 
normal ventricular mass was 15 and those with increased LV mass were 20. 
No statistically significant correlation was found between the two groups 
with regard to the risk factor, diabetes (p = 0.486). Thus, presence of diabetes 
in the study did not influence the ventricular mass of the study population. 
Similar finding was seen in the study by Lawrence P. McMahon et al
 [99]
, 
where presence of diabetes in the study population did not seem to influence 
left ventricular mass in any group. 
SYSTEMIC HYPERTENSION AND LVMI 
In our study population of 70, 40 patients were having hypertension (57%) 
and were on treatment for it. Of the 40 patients, 15 patients had normal 
ventricular mass and 25 patients had increased left ventricular mass. This 
correlation between the two group was not statistically significant (p = 
0.824). 
But, in the study by Daniel E Jesuorobo et al
 [96]
, most patients in the study 
population had hypertension (70.7%) and demonstrated a statistically 
significant difference in systolic blood pressure between those with and 
without left ventricular hypertrophy. 
 
 
 
 
SYSTOLIC BLOOD PRESSURE AND LVMI 
In our study, hypertensive patients who were under control with medications 
were taken as the study population; to eliminate the bias of uncontrolled 
hypertension inducing left ventricular hypertrophy. Elevated systolic blood 
pressure is a well-known independent factor for left ventricular mass index. 
But in our study, the risk factor was eliminated from the study population, so 
that the influence of the other risk factors for LVH could be studied well. 
 Thus, the mean systolic blood pressure in the normal group was 124.44 
and in the abnormal group were 122.87.  No statistically significant 
difference was found between the two groups (p = 0.65). 
In a study by Lawrence P. McMahon et al
 [99]
, elevated systolic blood 
pressure was found to contribute to left ventricular hypertrophy. Both volume 
and pressure overload caused the twin processes of an increase in left 
ventricular cavity and wall thickness. 
In the study by Kosaku Nitta et al
 [100]
, systolic blood pressure was 
independent risk factors for left ventricular hypertrophy. 
In the study by Yilmaz BA et al
[102]
, one of the independent predictor of the 
final left ventricular mass index was baseline day-time systolic blood 
pressure (p = 0.01) 
 
 
DIASTOLIC BLOOD PRESSURE AND LVMI 
In our study, the mean diastolic blood pressure in the normal group was 81.93 
and in the abnormal/ increased left ventricular mass group was 79.87 which 
was not statistically significant (p = 0.131).Thus, the diastolic blood pressure 
in chronic kidney disease is not an independent risk factor for left ventricular 
hypertrophy as suggested in our study. 
Similar results were seen in the study by XueSen Cao et al
 [97]
, where 
systolic blood pressure but not diastolic blood pressure was accepted as a risk 
factor for left ventricular hypertrophy in the hemodialysis population.  
SERUM ALBUMIN AND LVMI 
In our study population, the mean serum albumin value in the normal group 
was 2.934 and in the increased LV mass group was 2.781, thus there was no 
statistically significant difference between the either groups with regard to 
serum albumin level. Thus, the serum albumin did not independently predict 
the risk for left ventricular hypertrophy in chronic kidney disease patients in 
this study (p = 0.12). 
In the study by Kimura et al
 [103]
, univariate analyses revealed that serum 
albumin was significantly different between the groups with and without left 
ventricular hypertrophy. Stepwise logistic regression analysis showed that 
 
 
serum albumin was an independent risk factor for left ventricular 
hypertrophy. 
SERUM CHOLESTEROL AND LVMI 
In our study, the mean serum cholesterol in the normal LV mass group was 
206.07 and in the abnormal left ventricular mass group was 198.52 which 
was not statistically significant for the two groups (p = 0.667). Thus, serum 
cholesterol level did not independently predict the risk for left ventricular 
hypertrophy in CKDIn the study by Daniel E Jesuorobo et al
 [96]
, variable 
like total cholesterol, HDL-cholesterol and LDL-cholesterol had significantly 
higher mean values in patients compared with controls but none had any 
correlation with left ventricular mass index similar to our study results. 
SERUM TRIGLYCERIDES AND LVMI 
In our study population, the mean triglycerides level in the normal left 
ventricular mass group was 166.24 and in the abnormal group was 167.07 
which did not have a statistically significant correlation between the either 
groups (p = 0.895). 
In the study by Daniel E Jesuorobo et al
[96]
, variable like serum triglycerides 
had significantly higher mean values in patients compared with controls but 
none had any correlation with left ventricular mass index similar to our study. 
 
 
 
 
SERUM ALKALINE PHOSPHATASE AND LVMI 
In our study population, the mean level of serum alkaline phosphatase in the 
normal group was 285.86 and in the abnormal left ventricular mass group 
was 290.65 which was not statistically significant. The p value for this 
correlation was 0.451 and thus serum ALP did not independently predict the 
risk for left ventricular hypertrophy. 
But in the study by Harnett J.D. et al
[101]
, the most important factor which 
independently related to left ventricular hypertrophy in all the patients 
studied, using multiple logistic regression was serum alkaline phosphatase 
which probably reflects hyperparathyroidism (p = 0.03). In a subset of 
patients with severe left ventricular hypertrophy (left ventricular wall 
thickness > 1.4 cm), a high serum alkaline phosphatase level was the best 
predictor of LVH (p < 0.001). 
HEMOGLOBIN AND LVMI 
In our study, the mean hemoglobin value in the normal group was 8.33 and in 
the abnormal group was 8.44 which did not have a statistically significant 
relation in either groups (p = 0.406). Thus in this study, the severity of 
anaemia did not predict the left ventricular dimension and thickness 
 
 
 
In the study byDaniel E Jesuorobo et al
 [96]
, the hemoglobin levels of the 
study population had a negative correlation with left ventricular mass index 
and it was statistically significant. 
BLOOD UREA AND LVMI 
No significant correlation was found between the amount of blood urea and 
the left ventricular wall thickness in chronic kidney disease. The mean serum 
urea concentration in the normal group was 76.97 and in the abnormal 
increased LV mass group was 36.531 which did not hold a statistically 
significant relation (p = 0.41). 
SERUM CREATININE AND LVMI 
Our study population had significant difference in serum creatinine between 
the two groups. The mean serum creatinine in the normal LV group was 
1.873 and in the increased left ventricular mass group were 6.515.  These two 
groups had a statistically highly significant difference with regard to serum 
creatinine (p = <0.001).  Thus serum creatinine value is an independent 
predictor for the risk of left ventricular hypertrophy in chronic kidney disease 
patients. 
Similar findings were obtained in a study by Harnett J.D.et al
 [101]
, where 
one of the most important factor associated with LVH in chronic kidney 
disease was high serum creatinine. 
 
 
GLOMERULAR FILTRATION RATE AND LVMI 
In our study, we found a statistically high significant correlation between 
declining GFR (Stage 4/5) with increased left ventricular thickness in chronic 
kidney disease patients. The mean glomerular filtration rate in the normal 
group was 58 – 64 ml/min and in the increased left ventricular mass group, 
the mean GFR value was 17 ml/min, giving a high significant statistical 
correlation between the two groups (p = <0.001). Thus, there was a strong 
negative correlation between glomerular filtration rate and left ventricular 
hypertrophy, the declining GFR being an important and independent 
predictor of increased left ventricular mass index. 
In a study by Daniel E Jesuorobo et al
 [96]
, estimated glomerular filtration 
rate correlated negatively with left ventricular mass index and also emerged 
the strongest predictor of LVMI in patients with CKD accounting for 24.1% 
of the variation in LVMI. 
In the study by XueSen Cao et al
 [97]
, even in the predialysis population, the 
prevalence of LVH increases with progressive decline in renal function. 
In the study by Lawrence P. McMahon et al
 [99]
, low glomerular filtration 
rate contributed to the initial presence of left ventricular hypertrophy. 
In the study by Yilmaz BA et al
 [102]
, the independent predictor of the left 
ventricular mass index was decrease in the glomerular filtration rate (p = 
 
 
0.002). Left ventricular hypertrophy is quite frequent among patients with 
stage 3 or 4 chronic kidney disease, and its prevalence increases while 
glomerular filtration rate decreases during the follow-up. 
PROTEINURIA AND LVMI 
In our study, the mean urine spot PCR value in the normal group was 1.8 and 
in the increased left ventricular mass group was 10.8 which had a highly 
significant statistical correlation with a p value less than 0.001. Similarly in 
the study by Emily P. McQuarrie et al
 [104]
, proteinuria was significantly and 
independently associated with left ventricular mass index patients with 
chronic kidney disease. This relationship was independent of the baseline 
systolic blood pressure. Urine spot PCR values had a significant correlation 
with the left ventricular hypertrophy in Emily McQuarrie study. 
 Regarding 24 hour proteinuria excretion, in our study, the mean proteinuria 
in the normal group was 1821 mg and in the abnormal group was 8621 mg 
which had a highly significant p value of less than 0.001. This positive 
correlation had a statistically significant relation. Emily P. McQuarrie et al 
study also found a significant correlation of 24 hour proteinuria with left 
ventricular hypertrophy in chronic kidney disease. 
BODY SURFACE AREA AND LVMI: 
 
 
No significant correlation was found between the left ventricular thickness 
and body surface area. The mean BSA in the normal group was1.5962 and in 
the abnormal group was 1.5996, showing no significant correlation between 
the two groups (p = 0.713). 
SERUM CREATININE AND PROTEINURIA 
According to our study, there was a highly significant statistical correlation 
between the serum creatinine value and the amount of proteinuria (urine spot 
PCR & 24 hour proteinuria) in chronic kidney disease. As the stage of the 
CKD worsened, both the serum creatinine and the quantity of protein 
excretion exponentially increase. The p value for the two groups is 
statistically highly significant (p = <0.001). 
CREATININE CLEARANCE AND PROTEINURIA 
According to our study, there was a negative correlation between the 
glomerular filtration rate and the amount of protein excreted. As the 
glomerular filtration rate decreases, the quantity of protein excreted increases 
progressively. There was a highly significant correlation between the 
glomerular filtration rate and urine spot PCR (p = <0.001). Also, the 24 hour 
proteinuria showed a significant correlation with that of the glomerular 
filtration rate, p value being less than 0.001. 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS OF THE  
     STUDY 
 
 
 
 
 
 
 
LIMITATION OF THE STUDY 
1. This study is done in a small number of patients. Study in a large sample 
of population is further needed. 
2. Chronic kidney disease patients who were managed on conservative 
management were the subjects of this study.  Thus, the effect of 
hemodialysis and its effect on left ventricular thickness could not be 
obtained from this study. 
3. Early diagnosis of diseases like diabetes, hypertension and chronic kidney 
disease is not possible in all the patients. Hence the duration of the 
underlying risk factors, control of the blood pressure and glycaemic prior 
to the treatment could not be commented. 
4. The left ventricular wall thickness is best measured by the cardiac MRI 
study. LVMI measured by 2D echocardiography has a lower sensitivity 
when compared to the gold standard investigation. 
5. The left ventricular thickness measured by 2D echocardiography is prone 
for inter observer variations. 
6. A follow up study measuring and monitoring the left ventricular mass 
regularly in chronic kidney disease was not done, which could have 
provided valuable information in the treatment and management of uremic 
cardiomyopathy of chronic kidney disease patients. 
 
 
 
 
 
 
 
 
 
 
   CONCLUSION 
 
 
 
 
 
 
 
 
CONCLUSION 
 Glomerular filtration rate and the amount of proteinuria significantly 
influence the left ventricular wall thickness in chronic kidney disease 
patients.  
 Declining GFR had a strong negative correlation with left ventricular 
mass, where the amount of protein excreted positively predicted the 
significant risk of left ventricular hypertrophy in these patients.  
 These predictors of LV mass could be easily measured and are highly 
sensitive and specific for the same. 
 Hence routine measurement of these variables, and its correlation to 
left ventricular thickness could be easily ascertained compared to the 
costly investigations like cardiac MRI and Echocardiography.  
 On arriving at a suspicion of possible LV hypertrophy, rigorous 
measures to reduce protein excretion and frequent hemodialysis 
session could improve the patients’ survival from the deadly 
cardiovascular diseases. 
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DATA COLLECTION   
    
     FORM 
 
 
 
 
 
 
 
 
 
 
 
 
HISTORY 
1. NAME    : 
2. AGE     : 
3. SEX     : 
4. OCCUPATION   : 
5. LOCATION   : 
6. CHRONIC KIDNEY DISEASE: Conservative management 
        Haemodialysis (arteriovenous fistula) 
        Haemodialysis (jugular access) 
        Peritoneal dialysis 
        Renal transplant 
7. COMORBIDITY    
    DIABETES 
    SYSTEMIC HYPERTENSION 
    CORONARY HEARTDISEASE 
    CEREBROVASCULAR ACCIDENT 
    PULMONARY TUBERCULOSIS 
    BRONCHIAL ASTHMA/ COPD 
    CHRONIC PULMONARY DISEASE 
    EPILEPSY 
    CHRONIC LIVER DISEASE 
8. SMOKING     : 
9. ALCOHOL USE    : 
10. MAJOR SURGERY   : 
11. MAJOR TRAUMA   : 
12. DRUG INTAKE    : 
 
 
EXAMINATION 
BLOOD PRESSURE 
o SYSTOLIC BLOOD PRESSURE : 
o DIASTOLIC BLOOD PRESSURE : 
o PULSE PRESSURE   : 
o MEAN ARTERIAL PRESSURE : 
PULSE RATE      : 
CARDIOVASCULAR SYSTEM   : 
RESPIRATORY SYSTEM    : 
GASTROINTESTINAL SYSTEM   : 
CENTRAL NERVOUS SYSTEM   : 
PALLOR       : 
ICTERUS       : 
CLUBBING      : 
CYANOSIS       : 
PEDAL EDEMA      : 
SIGNIFICANT LYMPHADENOPATHY  : 
HEIGHT       : 
WEIGHT       : 
BODY MASS INDEX     : 
BODY SURFACE AREA    : 
WAIST CIRCUMFERENCE    : 
HIP CIRCUMFERENCE    : 
WAIST HIP RATIO     : 
 
 
INVESTIGATIONS 
COMPLETE BLOOD COUNT  
 Total count    : 
 Differential count   : 
 Haemoglobin    : 
 Platelet count   : 
 Erythrocyte sedimentation rate : 
RENAL FUNCTION TEST 
 Random blood sugar  : 
 Blood urea    : 
 Serum creatinine   : 
URINE EXAMINATION 
 Albumin    : 
 Sugar     : 
 Deposits    : 
 Urine spot PCR   : 
 24 hours proteinuria  : 
 24 hour creatinine clearance : 
LIVER FUNCTION TEST 
 Total protein   : 
 Serum albumin   : 
 Serum globulin   : 
 Serum alkaline phosphatase : 
 Serum bilirubin   : 
LIPID PROFILE 
 Serum total cholesterol  : 
 Serum triglycerides   : 
 
 
 
SERUM PHOSPHORUS    : 
ELECTROCARDIOGRAM   : 
eGFR       : 
K/ DOQI STAGING    : 
 
ECHOCARDIOGRAM 
 INTERVENTRICULAR SEPTAL THICKNESS IN DIASTOLE 
(IVSDd) 
 
 LEFT VENTRICULAR INTERNAL DIAMETER IN DIASTOLE 
(LVIDd) 
 
 LEFT VENTRICULAR INTERNAL DIAMETER IN SYSTOLE 
(LVIDs 
 
 LEFT VENTRICULAR POSTERIOR WALL THICKNESS IN 
DIASTOLE (LVPWDd) 
 
 EJECTION FRACTION (EF) 
 
 FRACTIONAL SHORTENING (FS) 
 
 LEFT VENTRICULAR MASS (LVM)( Devereux formula ) 
 
 LEFT VENTRICULAR MASS INDEX (BSA) 
 
 LEFT VENTRICULAR MASS (HEIGHT) 
 
 RELATIVE WALL THICKNESS (RWT) 
 
 CONCENTRIC/ ECCENTRIC LVH 
 
 SYSTOLIC DYSFUNCTION 
 
 DIASTOLIC DYSFUNCTION 
 
 
 
 
 
 
     
 
      MASTER CHART
 
 
 
 
 
NO.NAME AGESEXDurationDM SHT SBP DBP Sr.AlbuminHb Sr. ALPCHOL TGL B. UREAB.CREAT24CrCl ECrClMDRD stage of ckdUr.PCR24 pro LV MASS BSA LVMI
1 pooncholai 35 F 3 no no 118 84 3.2 9 200 118 100 29 0.8 98 93 87 1 0.76 762 67.4693 1.34629 50.11
2 Rajendran1 46 M 2 yes yes 140 86 3 8 220 273 153 42 1 97 85 86 1 0.57 571 95.0356 1.7756 53.52
3 madurai 45 M 3 yes yes 138 90 2.8 9.5 210 320 157 52 1.1 91 72 77 2 0.85 855 80.4922 1.4699 54.87
4 Subramani 39 M 1 yes yes 128 80 2.6 8.4 180 278 297 68 0.9 90 78 76 2 0.68 682 100.01 1.6586 60.30
5 kaliammal 32 F 5 no no 116 80 2.4 7.5 200 120 125 100 1.2 87 84 76 2 0.86 857 99.8191 1.6278 61.32
6 rathnammal 56 F 3 yes yes 134 84 3.4 6 240 167 218 34 0.9 90 72 69 2 1.18 1200 105.502 1.6431 64.21
7 Sarada 45 F 1 yes no 118 86 2.5 9.5 280 247 188 210 1.1 88 67 67 2 1.21 1200 109.838 1.64766 66.66
8 subaidha 54 F 4 yes no 136 86 3.5 8 360 216 260 39 1.2 83 64 70 2 1.35 1300 116.845 1.7076 68.43
9 Meena 24 F 4 no no 114 80 3.4 9.5 400 120 145 130 1.5 80 68 65 2 1.44 1400 103.621 1.4977 69.19
10 Manickam 54 M 4 yes yes 132 84 3.5 8.4 280 169 162 40 1.1 82 71 74 2 1.67 1700 96.2175 1.3579 69.77
11 Ponraj 46 M 5 yes yes 138 88 3.2 8.4 250 223 119 58 1.4 78 75 71 2 1.58 1600 129.888 1.786 72.73
12 vembu 30 F 4 no no 132 80 3 6.4 290 127 165 28 1.5 70 65 60 2 1.64 1600 91.2614 1.2402 73.59
13 vijayakumar 25 M 2 no no 100 70 2.8 7.5 310 150 80 110 1.5 72 74 60 2 0.8 800 124.83   1.678 74.39
14 hazira begum 48 F 3 yes no 110 76 2.8 7 380 284 218 80 1.9 65 64 60 2 1.06 1100 134.283 1.791 74.98
15 Meera 24 F 2 no no 106 70 3 6 420 145 150 46 1.8 62 65 57 2 1.5 1500 122.729 1.4896 82.39
16 rajendran2 34 M 5 yes no 118 78 2.8 8.4 240 280 210 61 2 56 68 60 2 1.9 1900 150.627 1.732 86.97
17 Srinivas 35 M 4 yes no 120 80 3.2 10 350 301 169 87 2.1 53 65 58 3 1.45 1400 165.556 1.8643 88.80
18 swarnam 54 F 3 yes yes 136 86 3.5 8.4 360 378 137 27 2 50 50 48 3 1.16 1200 150.484 1.6456 91.45
19 veerammal 32 F 4 no no 108 74 2.8 8.4 330 120 120 180 2.3 50 46 46 3 1.75 1700 138.414 1.47381 93.92
20 Vananakshatram45 F 3 yes no 140 90 3.2 8 420 217 178 39 2.2 51 46 40 3 1.85 1800 168.179 1.7643 95.32
21 amaresan 50 M 4 yes yes 102 78 2.4 9.8 410 213 274 120 2.4 48 60 55 3 2.69 2700 161.488 1.57759 102.36
22 zarina 54 F 3 yes yes 114 74 2.1 8.2 190 196 168 180 2.5 48 44 45 3 2.88 2900 178.405 1.736 102.77
23 Surendar 36 M 3 no yes 136 84 3 9.6 200 200 188 100 2.6 42 50 54 3 2.33 2300 154.443 1.4643 105.47
24 Pitchai 50 M 4 no yes 124 82 2.5 8.4 220 140 135 58 2.5 39 48 45 3 2.6 2600 180.483 1.6989 106.23
25 desamma 40 F 5 no no 132 80 2.8 9.4 240 180 168 58 2.4 38 43 35 3 2.67 2700 147.458 1.3462 109.54
 
 
 
 
 
26 Mariappan 36 M 3 no yes 130 90 2.4 8.6 260 229 130 80 2.6 41 45 45 3 3.56 3600 176.633 1.5678 112.66
27 annakilli 52 F 4 yes yes 140 86 3.2 9.2 280 249 174 90 2.9 35 38 40 3 3.57 3600 192.801 1.6832 114.54
28 Srimathi 27 F 3 no no 120 80 3.4 8.8 300 136 140 110 3 34 40 42 3 4 3900 161.735 1.40786 114.88
29 amsa 48 F 4 yes yes 116 78 2.7 8 320 298 178 120 3.5 32 35 34 3 3.75 3800 197.469 1.71656 115.04
30 Mohana 50 F 5 no yes 134 84 2.6 9.6 420 185 140 70 3.1 30 35 32 3 3.6 3600 208.443 1.7857 116.73
31 Selvarani 36 F 1 yes no 126 82 3 9.4 400 200 150 145 3.2 32 34 30 3 3.59 3600 186.36 1.5851 117.57
32 James 45 M 5 no yes 136 86 2.4 8 380 216 88 80 2.8 40 40 42 3 3.25 3300 160.876 1.3676 117.63
33 Mary 21 F 2 no no 104 74 2.8 7.8 360 120 150 150 3.2 24 21 20 4 3.64 3600 159.057 1.3365 119.01
34 mani 38 M 5 no yes 126 80 3 8.4 240 189 164 40 2.9 36 38 38 3 3.52 3500 194.702 1.6309 119.38
35 Sumangali 56 F 4 yes yes 132 82 3.1 8 280 219 163 56 3.5 21 18 20 4 3.31 3300 162.548 1.3583 119.67
36 mariammal 24 F 2 no no 110 80 2.5 7 220 145 180 90 3.7 19 18 20 4 4.2 4200 179.635 1.4432 124.47
37 velu 43 M 5 no yes 130 90 2.6 9 230 160 155 56 4.1 39 34 36 3 4.09 4100 212.129 1.7029 124.57
38 Marudhammal51 F 3 yes yes 140 90 2.6 8.4 340 171 316 84 4 15 14 18 4 4.1 4100 207.364 1.6527 125.47
39 sampoornam 45 F 5 yes yes 110 74 2.4 6.9 220 215 118 91 4.7 14 14 15 4 5.1 5100 211.174 1.6733 126.20
40 Sangeetha 34 F 2 no no 106 80 2.5 8.1 240 159 158 53 4.6 14 15 15 4 5.56 5600 221.539 1.74922 126.65
41 Vimala 37 F 3 no no 104 74 2.5 5.7 290 246 128 65 4.2 15 16 15 4 5.23 5200 242.965 1.83301 132.55
42 Latha 35 F 4 yes no 110 76 3 6.4 320 152 114 39 4.4 16 16 15 4 5.76 5800 193.66 1.4585 132.78
43 Pooranam 54 F 5 yes yes 140 86 3.4 8.4 250 183 226 86 4.6 13 14 14 4 6.14 6100 253.184 1.8637 135.85
44 Palaniammal 26 F 3 no no 98 70 3.2 9.6 190 100 110 70 4.9 13 15 14 4 6.07 6100 181.734 1.33746 135.88
45 ArivudaiNambi32 M 4 no yes 124 82 3.1 10 260 187 150 110 4.9 37 28 30 3 7 5000 256.044 1.87057 136.88
46 Kalyani 26 F 2 no no 110 74 2.5 9.4 270 120 106 75 5 11 14 11 5 7.76 7800 182.59 1.3225 138.06
47 Sheela 45 F 1 yes no 128 80 2.6 8.8 300 168 118 85 5.2 11 13 11 5 8.75 7100 242.983 1.75098 138.77
48 Iqbal Basha 46 M 3 no yes 138 86 2.7 9.5 280 176 250 80 5.3 35 30 32 3 6.74 6700 257.818 1.84763 139.54
49 john peter 48 M 2 no yes 140 84 2.8 8.8 290 210 124 105 5.4 30 25 31 4 8.86 7900 230.281 1.6062 143.37
50 Manohar 46 M 2 no yes 134 80 2.8 9 200 187 150 100 5.5 32 28 34 3 8.55 8200 200.777 1.3856 144.90
 
 
 
 
 
51 Sambanthan 42 M 3 no yes 130 78 2.1 8.8 300 152 114 98 5.7 30 25 24 4 8.5 8500 299.523 2.05646 145.65
52 Jeganathan 47 M 5 yes yes 128 76 2.4 8.4 280 220 106 140 5.8 25 28 26 4 9.57 9600 252.111 1.73094 145.77
53 Jeyakumar 25 M 2 no no 108 80 2.6 8.6 310 100 180 200 6 24 26 20 4 9.72 9700 263.146 1.80249 145.99
54 Suresh 47 M 5 yes no 116 80 2.7 9.4 210 189 264 80 6.2 22 20 24 4 11.25 10500 242.532 1.66129 145.99
55 Parveen Banu43 F 4 yes yes 140 86 2.7 9.5 260 219 163 78 6.5 14 12 12 5 9.375 9600 239.902 1.61051 148.96
56 Chandra 50 F 5 yes yes 134 80 3 9.6 320 173 218 60 6.5 14 10 10 5 9.23 10300 267.442 1.78342 149.96
57 Ganga 43 F 1 no yes 130 80 3.2 8 220 160 155 68 6.9 12 10 10 5 9.6 10600 242.276 1.5854 152.82
58 Rajkumari 56 F 5 yes no 128 84 3.4 9 240 171 316 70 7 10 8 8 5 9.736 11500 263.403 1.7019 154.77
59 Sahul Hameed28 M 4 no no 110 76 3.5 9 330 128 159 80 7.2 18 18 15 4 13.39 10000 219.968 1.42025 154.88
60 Kolandaivel 48 M 4 no yes 140 86 2.4 7.6 230 273 153 38 7.4 17 15 13 4 13.75 10850 228.151 1.4583 156.45
61 kuppan 45 M 6 no yes 138 84 2.8 6.5 340 320 157 102 7.8 19 15 11 4 14.44 11000 244.351 1.5365 159.03
62 eswaran 49 M 6 yes yes 126 80 2.4 8 240 278 297 130 8 20 14 10 5 16.67 10800 253.125 1.5585 162.42
63 Deenadayalan39 M 2 yes no 136 84 2.6 8.4 350 190 219 65 8.2 16 18 15 4 17.83 11200 270.147 1.64744 163.98
64 Raman 37 M 3 no yes 118 72 2.4 9 220 167 162 43 8.1 12 10 12 5 18.41 11500 222.528 1.3458 165.35
65 Subramani 52 M 6 no yes 100 76 2.8 6.8 250 226 118 48 8.5 14 10 10 5 18.18 12100 284.656 1.71605 165.88
66 Ganesh 29 M 4 no no 120 78 3 7.4 360 320 150 80 8.7 13 12 11 5 17.5 12000 209.886 1.24567 168.50
67 Dorairaj 48 M 6 yes yes 116 74 3.12 6.1 200 265 267 110 9 10 9 8 5 18.91 12450 313.247 1.77096 176.88
68 Palani 22 M 2 no no 120 80 3.2 8.4 370 98 110 62 9.4 9 10 10 5 17.5 12500 293.538 1.6585 176.99
69 Vasu 25 M 2 no no 110 70 3.4 8.6 260 101 120 120 9.5 9 10 9 5 18.18 12000 239.862 1.3484 177.89
70 Chinnasamy 56 M 8 yes no 138 80 2.8 9 380 184 182 58 9.8 8 8 7 5 18.91 12800 279.741 1.5432 181.27
71 Ravi 56 M 7 no yes 140 90 2.5 9.4 190 378 137 180 10 7 8 7 5 20 13000 329.794 1.7492 188.54
72 Chelladurai 37 M 5 yes no 118 74 2.6 9.6 390 223 119 145 11 7 8 7 5 20.91 13100 337.547 1.77227 190.46
73 Dilli Babu 51 M 6 no yes 124 80 2.4 9.2 270 301 169 110 12 6 7 6 5 18.96 13200 264.329 1.3856 190.77
74 ameerudin 19 M 2 no no 100 78 2.8 8.4 420 223 119 150 13 4 4 4 5 20.45 13500 261.244 1.3693 190.79
75 Sheik Mujibdeen48 M 3 yes yes 120 86 3 8.4 400 247 188 120 13 3 4 4 5 21 14000 278.579 1.4567 191.24
 
 
Dur   - Duration 
DM   - Diabetes Mellitus 
SHT  - Systemic Hypertension 
B.U   - Blood Urea (mg/dL)  
B.Cr  - Blood Creatinine (mg/dL) 
24CrCl - 24 hour Creatinine Clearance (ml/min) 
ECrCl - Estimated Creatinine Clearance using Cockcroft Gault Formula  
    (ml/min) 
MDRD - Estimated Creatinine Clearance using Modified Diet in Renal  
     Disease formula (ml/min) 
Ur.PCR - Urine Spot Protein Creatinine Ratio 
24 pro - 24 hours proteinuria (mg/dL) 
LVmass - Left Ventricular Mass (g) 
BSA  - Body Surface Area (m2) 
LVMI - Left Ventricular Mass Index (g/m2) 
 
 
 
 
 
 
 
 
 
 
  ABBREVIATIONS 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
 
CKD  Chronic Kidney Disease 
 
GFR  Glomerular Filtration Rate 
 
PCR  Protein Creatinine Ratio 
 
LVMI Left Ventricular Mass Index 
 
NFK  National Kidney Foundation 
 
KDOQI Kidney Disease Outcomes Quality Initiative 
  
ESRD End Stage Renal Disease 
 
DM  Diabetes Mellitus 
 
HT  Hypertension 
 
CVD  Cardio Vascular Disease 
 
LVH  Left Ventricular Hypertrophy 
 
 
 
CAD  Coronary Artery Disease 
 
mTOR Mammalian Target Of Rapamycin 
 
2D/3D 2 Dimensional/ 3 Dimensional 
 
CT  Computed Tomography 
 
CMRI Cardiac Magnetic Resonance Imaging 
 
NTproBNP N Terminal Prohormone Brain Natriuretic Peptide 
 
Trop T  Troponin T 
  
ACE  Angiotensin Converting Enzyme 
 
ARB  Angiotensin Receptor Blocker 
 
RAS  Renin Angiotensin System 
 
LDL  Low Density Cholesterol 
 
Na+ K+ ATPase Sodium Potassium Adenosine TriPhosphatase 
 
PI3K  Phospho – inositide 3 Kinase 
 
PPAR Peroxisome Proliferator Activated Receptor 
 
 
 
ERK  Extracellular signal- Related Kinases   
  
CTS  Cardio tonic Steroids 
 
ET 1  Endothelin 1 
 
PTH  Parathormone 
 
IL 1α  Interleukin 1-alpha 
 
IL 6  Interleukin 6 
 
TNFα  Tumour Necrosis Factor – alpha 
 
AT II  Angiotensin II 
 
HDL  High Density Cholesterol 
 
LV  Left Ventricle 
 
TGF  Transforming Growth Factor 
 
MDRD formula - Modification of Diet in Renal Disease formula 
 
 
 
 
 
 
 
 
 
 
 
 
ETHICAL COMMITTEE  
    CLEARANCE CERTIFICATE 
 
 
A  
 
 
 
 
 
 
 
 
   PATIENT CONSENT FORM 
 
 
 
 
 
 
 
 
 
 
 
÷{õ¯õÎ J¨¦uÀ £iÁ® 
Bµõ´a]°ß ÂÁµ®:  
Bµõ´a] ø©¯®: Aµ_ RÌ£õUP® ©¸zxÁU PÀ¿¶ ©¸zxÁ©øÚ 
÷{õ¯õÎ°ß ö£¯º:      ÷{õ¯õÎ°ß Á¯x: 
£vÄ Gs: 
 1. ÷©ØSÔ¨¤mkÒÍ Bµõ´a]°ß ÷{õUPzøu²® £¯øÚ²® ¬ÊÁx©õP 
¦¶¢xöPõs÷hß. ÷©¾® GÚx AøÚzx \¢÷uP[PøÍ²® ÷Pmk 
AuØPõÚ ÂÍUP[PøÍ²® öuÎÄ£kzvU öPõs÷hß. 
 
2. ÷©¾® C¢u Bµõ´a]US GÚx ö\õ¢u Â¸¨£zvß ÷£¶À £[÷PØQ÷Óß 
GßÖ®, ÷©¾® G¢u ÷{µzv¾® GÆÂu ¬ßÚÔÂ¨¦ªßÔ C¢u 
Bµõ´a]°¼¸¢x Â»P ¬Êø©¯õÚ E¶ø© EÒÍøu²®, CuØS GÆÂu 
\mh ¤øn¨¦® CÀø» Gß£øu²® AÔ÷Áß. 
 
3. Bµõ´a]¯õÍ÷µõ, Bµõ´a] EuÂ¯õÍ÷µõ, Bµõ´a] E£¯zuõ÷µõ, Bµõ´a] 
÷£µõ]¶¯÷µõ, KÊ[Sö{Ô ö\¯ØSÊ EÖ¨¤ÚºP÷Íõ G¨÷£õx 
÷Ásk©õÚõ¾® GÚx AÝ©v°ßÔ GÚx EÒ÷{õ¯õÎ £vÄPøÍ C¢u 
Bµõ´a]UPõP÷Áõ AÀ»x GvºPõ» ¤Ó Bµõ´a]PÐUPõP÷Áõ 
£¯ß£kzvUöPõÒÍ»õ® GßÖ® ÷©¾® C¢u |£¢uøÚ {õß 
CÆÁµõ´a]°¼¸¢x Â»QÚõ¾® uS® GßÖ® J¨¦UöPõÒQ÷Óß. B°Ý® 
GÚx Aøh¯õÍ® \®£¢u¨£mh G¢u £vÄPÐ® (\mh§ºÁ©õÚ ÷uøÁPÒ 
uÂµ) öÁÎ°h¨£h©õmhx GßÓ EÖvö©õÈ°ß ö£¯¶À C¢u 
Bµõ´a]°¼¸¢x QøhUP¨ö£Ö® ¬iÄPøÍ öÁÎ°h ©Ö¨¦ 
öuÔÂUP©õm÷hß GßÖ EÖv¯ÎUQß÷Óß. 
 
   
4. C¢u Bµõ´a]US {õß ¬Ê©Úxhß \®©vUQß÷Óß GßÖ® ÷©¾® 
Bµõ´a]U SÊÂÚº GÚUS AÎUS® AÔÄøµPøÍ uÁÓõx ¤ß£ØÖ÷Áß 
 
 
 
GßÖ® EÖv¯ÎUQß÷Óß. 
5. C¢u Bµõ´a]USz ÷uøÁ¨£k® AøÚzx ©¸zxÁ¨ £¶÷\õuøÚPÐUS® 
JzxøÇ¨¦ u¸÷Áß GßÖ EÖv¯ÎUQß÷Óß. 
 
 6. C¢u Bµõ´a]US ¯õ¸øh¯ ÁØ¦Özu¾ªßÔ GÚx ö\õ¢u Â¸¨£zvß 
÷£¶¾® _¯AÔÄhÝ® ¬Ê©ÚxhÝ® \®©zvUQß÷Óß GßÖ Cuß -»® 
J¨¦UöPõÒQ÷Óß. 
 
÷{õ¯õÎ°ß øPö¯õ¨£® / ö£¸ÂµÀ øP÷µøP 
Ch®:     ÷uv: 
Bµõ´a]¯õÍ¶ß øPö¯õ¨£® 
Ch®:     ÷uv: 
 
  
 
  
 
 
 
 
 
 
 
 
  TURNITIN ORIGINALITY REPORT 
 
 
 
 
 
 
 
 
  
 
 
 
 
